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7CHAPTER I
Introduction
Based on:
Idiopathic Rhinitis, the ongoing quest.
J.B. van Rijswijk, H.M. Blom and W.J. Fokkens
Allergy, 2004 in press
8ABSTRACT
The term rhinitis in daily practice is used for nasal dysfunction causing symp-
toms like nasal itching, sneezing, rhinorrhea and or nasal blockage. Chronic
rhinitis can roughly be classified into allergic, infectious or ideopathic rhini-
tis. When allergy, mechanical obstruction and infections have been excluded
as the cause of rhinitis, a number of poorly defined nasal conditions of partly
unknown aetiology and pathophysiology remain. The differential diagnosis of
nonallergic noninfectious rhinitis is extensive.
Although the percentage of patients with nonallergic noninfectious rhinitis
with a known cause has increased the last decades, still about 50% of the
patients with nonallergic noninfectious rhinitis has to be classified as suffering
from idiopathic rhinitis, or rather e causa ignota. Specific immunological,
clinical and sometimes radiological and functional tests are required to
distinguish known causes. Research to the underlying pathophysiology of
idiopathic rhinitis has moved from autonomic neural dysbalans to
inflammatory disorders (local allergy), the nonadrenergic noncholinergic
sensory peptidergic neural system and central neural hyperesthesia, still
without solid ground or proof.  This review summarizes the currently known
causes for nonallergic noninfectious rhinitis and possible treatments. Also
possible pathophysiological mechanisms of idiopathic rhinitis are discussed.
9INTRODUCTION
Rhinitis is a very common disorder known to all of us. Most people suffer
from an infectious viral rhinitis, or common cold, at least once a year. It
generally proofs to be a self limiting disease disappearing in 1 or 2 weeks
without specific treatment. This in contrast to chronic rhinitis, affecting upto
20% of the general population (1).
Chronic rhinitis can be due to common factors such as allergy, smoking or
less common factors such as xylometazoline abuse or cystic fibrosis.  Rhinitis
means inflammation of the nasal mucosal membrane. However, markers of
inflammation are not examined in routine clinical work. Therefore, the term
rhinitis in daily practice is used for nasal dysfunction causing symptoms like
nasal itching, sneezing, rhinorrhea and or nasal blockage (1).
RHINITIS CLASSIFICATION
Chronic rhinitis can roughly be classified into allergic, infectious or
nonallergic-noninfectious (Figure 1) (1-3). The exact figures are unknown
but most ENT clinics report a 50-50 % division between allergic and
nonallergic patients in perennial rhinitis (4).
Figure 1. Schematic representation of allergic, infectious and nonallergic/noninfectious
rhinitis.
Allergic
Infectious Nonallergic-Noninfectious
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Allergic rhinitis is clinically defined as a symptomatic disorder of the nose
induced by an IgE-mediated inflammation after allergen exposure of the nasal
mucosa. The diagnosis of allergy is based on diagnostic tests for allergy, like
skin prick tests and or measurement of specific serum IgE.
The disease is nonallergic when allergy has not been proven by proper al-
lergy examination (history, skin prick testing, measurement of serum specific
IgE antibodies).
Rhinitis is called noninfectious when the persistent nasal discharge is clear
and watery, and not purulent. Detection of micro-organisms (viruses, bacte-
ria, fungi) is generally not used as a diagnostic criterion.
When allergy, mechanical obstruction and infections have been excluded as
the cause of rhinitis, a number of poorly defined nasal conditions of partly
unknown aetiology and pathophysiology remain. The differential diagnosis
of nonallergic noninfectious rhinitis is extensive (5) (Table 1). The mechanisms
are only partly unravelled. If the pathophysiology is unknown, the term
idiopathic rhinitis (IR) is used.
O ccu p atio n a l (Ir ritan t)
D ru g  in d u ced :
R h in itis  M ed icam en to sa  (to p ica l v aso co n stric tiv e  α -ad ren ocep to r ag o n is ts)
O th e r d ru g s
H o rm o n a l
R h in itis  o f th e  E ld erly
N A R E S
S m o k in g
Id io p ath ic  R h in itis  (e  cau sa  ig n o ta)
Table 1. The differential diagnosis of nonallergic noninfectious rhinitis
11
NONALLERGIC NONINFECTIOUS PERENNIAL RHINITIS
Nonallergic noninfectious perennial rhinitis can be divided in disorders with
known and in disorders with unknown pathology.
Occupational nonallergic rhinitis
Occupational rhinitis arises in response to an air-borne agent present in the
workplace. Many occupational agents are irritant and nonallergic hyper-re-
sponsiveness may occur.
Most occupational agents inducing nonallergic rhinitis are small molecular
weight compounds such as isocyanates, aldehydes, ninhydrin, and pharma-
ceutical compounds (6, 7). More than 250 different chemical entities have
been identified. Although these can act as reactive haptens, non-immuno-
logical mechanisms are common.
Some compounds, like chlorine, can induce irritant rhinitis in 30 to 50% of
the exposed workers (8, 9).
Rhinitis Medicamentosa
Long-term use of topical nasal vasoconstrictors (like xylometazoline-
hydrochloride and other α-adrenoceptor agonists) often results in rhinitis
medicamentosa with possible histologic mucosa changes and drug addiction.
Rhinitis medicamentosa can be defined as a condition of nasal hyperreactivity,
mucosal swelling, rebound nasal congestion and tolerance that is induced,
or aggravated, by the overuse of topical vasoconstrictors with or without a
preservative (10). In the Netherlands this pathology is regularly seen in the
second echelon since the over-the-counter availability of these medicines.
Generally these patients can be adequately treated by lucid exposition,
vasoconstrictor withdrawal and a topical corticosteroid spray to alleviate
the withdrawal process (11). After a successful vasoconstrictor withdrawal
a possible remaining nasal disorder (if any) can be treated.
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Other drugs inducing nonallergic rhinitis
A range of medications is known to cause nasal symptoms. ACE inhibitors,
reserpine, hydralazine, guanethidine, methyldopa, α-adrenoceptor antagonists
such as prazosin and phentolomine , ß-blockers, immunosuppresives, oral
contraceptives, aspirin, and other non-steroidal anti-inflammatory agents have
all been associated with nasal symptoms, as have intra-ocular ophthalmic
preparations (ß-blockers) (1, 12). Also psychotropic agents like thioridazine,
chlordiazepoxide, chlorpromazine, perphenazine, amitriptyline, and
alprazolam can have nasal side-effects (13) (Table 2).
Table 2. Drugs influencing nasal  function
Medicin group: Examples:
Nasal vasoconstrictors oxymetazoline,  xylometazoline,
ephedrine,
ACE inhibitors benazepril, captopril, cilazapril, enalapril,
fosinopril, lisinopril, perindopril, ramipril,
quinapril, trandolapril
Antihypertensiva guanfacine, reserpine, hydralazine,
methyldopa, guanethidine,
α- adrenoceptor antagonists prazosin, phentolomine
β- blockers (also intra-ocular) carvedilol, propranolol, sotalol, tertatolol,
timolol, alprenolol, oxprenolol, pindolol,
atenolol, betaxolol, bisoprolol, esmolol,
metoprolol, nebivolol, acebutolol,
celiprolol
Oral contraceptives
Aspirin and other NSAID’s
Psychotropics chlorpromazine, thioridazine,
chlordiazepoxide, amitriptyline,
perphenazine, alprazolam
Immunosuppresives cyclosporin, mycophenolic acid
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Hormonal rhinitis
Changes in the nose are known to occur during the menstrual cycle, puberty,
pregnancy and in specific endocrine disorders such as hypothyroidism and
acromegaly (14-16). Hormonal imbalance may also be responsible for the
atrophic nasal change in post-menopausal women. A persistent hormonal
rhinitis or rhino-sinusitis may develop during pregnancy in otherwise healthy
women. Its severity parallels the blood oestrogen level (99). The symptoms
usually quickly  disappear after delivery.
Rhinitis of the Elderly
Rhinitis of the elderly, or senilic rhinitis as it is called in the Netherlands, is
a characteristic clinical picture of the elderly patient suffering from a persistent
clear rhinorrhea without nasal obstruction or other nasal symptoms. Patients
often complain of the classical drop on the tip of the nose.  The first treatment
option is intranasal ipratropium bromid (up to 6 times a day) generally with
a good clinical result, suggesting an overactivity of the parasympathetic neural
system (17, 18).
Nonallergic Rhinitis with Eosinophilia Syndrome
The nonallergic rhinitis with eosinophilia syndrome (NARES) was origi-
nally described in 1981 by Jacobs (19).  He described patients with peren-
nial nasal symptoms of sneezing paroxysms, profuse watery rhinorrhea, and
pruritus of the nasopharyngeal mucosa in an “on-again-off-again” sympto-
matic pattern with a profound eosinophilia in the nasal smear (a nasal smear
with more than 25% eosinophils (20)) and no signs of allergy as tested by
skin prick testing and measurement of total and specific IgE in the nasal se-
cretion. Trigger factors associated by the patients with the acute onset of
nasal symptoms were non or unknown in 42%, weather changes in 31%,
odours in 15%, and noxious or irritating substances in 12%. The same sort of
patient group, with perennial symptoms of nasal hyperreactivity involving
sneezing, rhinorrhea, nasal obstruction, pruritus and frequent hyposmia was
later described by others (21, 22). Moneret-Vautrin suggested that NARES is
a precursor of aspirin sensitivity (21). Other groups were not able to find
eosinophilia in their population of nonallergic rhinitis patients (23, 24). This
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in contrast with a recent article of Powe describing nasal mucosa eosinophilia
in IR patients comparable to perennial allergic rhinitis patients (25). He sug-
gests that NARES is a local IgE mediated response (local allergy) which
does not result in systemic Th2 responses. Although local IgE production has
been made plausible already in the eighties by Platts-Mills and others (26),
the final prove came recently. It has been proven by at least two groups now
that local IgE production takes place in the nasal mucosa of allergic patients
(27, 28). However it remains to be proven that the same mechanism also
occurs in IR patients and whether this situation is stable over time or that
these patients, like has been shown in small children, develop allergic rhini-
tis in due time.
The definition of NARES as a subgroup of nonallergic noninfectious rhinitis
is relevant for therapy because they seem to respond well to nasal
corticosteroids (29). This in contrast to some other subgroups of nonallergic
noninfectious rhinitis.
Smoking Rhinitis
Smoke, in particular cigarette smoke, is known for its irritative effect on the
mucosa of the respiratory tract.  In passive smoking nonallergic children and
in smoking adults a mucosal cellular infiltration with Th2 like profile
including eosinophils, increased IgE+ cells and increased Il-4 is found (30-
32). Because smoking results in many individuals in the same clinical picture
of rhinitis with rhinorrhea and nasal obstruction it has to be viewed as a
cause of rhinitis in its own right. It might even be that (part of the) NARES
type of nonallergic rhinitis is caused by (passive) smoking inducing an ‘allergy
like’ inflammatory response (30, 31, 33).
Idiopathic Rhinitis
If all the possible causes are excluded, a significant part of the nonallergic
noninfectious rhinitis patients group persist. Syndromes of chronic rhinitis
with an unknown aetiology were formerly referred to by us as NANIPER.
Other terms like NINAR (noninfectious, nonallergic rhinitis) are also purely
descriptive (34).
In accordance with the ‘’World Health Organisation Initiative, Allergic Rhinitis
and its Impact on Asthma’’ (ARIA) (1), we will be using the term idiopathic
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rhinitis (IR) to describe this pathology. IR, formerly also called vasomotor
rhinitis, is a diagnosis of exclusion and is given to patients suffering from
perennial nasal congestion, rhinorrhea and or sneezing with no identifiable
aetiology. IR is unrelated to allergy, infection, structural lesions, polyposis
and other systemic diseases (as mentioned above).
IR, being a diagnosis per exclusionem, is solely diagnosed on patient
complaints. The first question therefore may be whether this disease really
exists. Occasional sneezing, rhinorrhea in the morning and upon exposure to
cold and polluted air can be considered a normal nasal response. Some persons
consider even slight nasal symptoms to be abnormal and seek medical advice
for that reason. Inquiry about the hours with daily symptoms may help to
make a distinction between a normal physiologic response and disease. Also
the use of a daily record card (DRC, Table 3) to score symptom duration and
intensity, possibly combined with peak nasal inspiratory flow measurements,
can give the physician more insight in the severity of the disease. Marked
Possible scores on the daily record chart
Nasal blockage:
(not being able to breathe freely through the nose)
Clear nasal discharge: (runny nose)
0 = absent
1 = between 0-1 h per half day
2 = between 1-2 h per half day
3 = more than 2 h per half day
Sneezing
Coughing
0 = absent
1 = less than 5 periods per half day
2 = between 5-10 periods per half day
3 = more than 10 periods per half day
Mucus production:
(yellow, green or brown)
0 = absent
1 = present
Table 3. Design of the daily record chart for defining nasal symptoms of IR patients.
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discrepancies between description of the problem at the first visit and data
from these daily measurements can be found (35).
DIAGNOSTIC CRITERIA FOR IDIOPATHIC RHINITIS
To exclude all known prevailing causes of chronic rhinitis one should at
least take a proper history (medication, smoking in previous 6 months, occu-
pation, etc.), adequately exclude commonly occurring inhalation allergies
(skin prick test and or specific serum IgE measurement) and perform
rhinoscopia anterior and nasendoscopy to exclude gross anatomical aberra-
tions and nasal polyps.
The mucosa of the nose and sinus are contiguous and thus chronic nasal
complaints can also be induced by a (accompanying) chronic sinusitis. When
in doubt of a possible chronic sinusitis one should not hesitate to perform
CT-scan imaging. However, if the history and the nasendoscopy lack criteria
pointing at possible sinus problems, CT-scan imaging is, in our opinion, not
obligatory for diagnosing IR.
Nasal complaints as a IR selection-criterion
After having excluded all known causes of chronic rhinitis one is left with a
group of patients with nasal complaints of unknown pathology (IR) (Table
4). This means that the studied patient group is probably a melting pot of
patients suffering from nasal complaints, with presumably variable
pathogenesis.  To study, select and define a group of patients, and more,
measure the effects of interventions, positive criteria are needed to make the
group as homogeneous as possible.  As IR is solely diagnosed on patients
complaints we use (and have used in all our previous studies to IR) a daily
record chart (Table 3) on which patients have to reach a minimum symptom
score to be classified as IR patient. The minimum is set, using the basis of the
definition of rhinitis put forward by Mygind and Weeke (36). In affected
patients, periods of nasal discharge, sneezing and / or congestion have to
persist for an average of at least 1-hour per day on at least five days during a
period of fourteen days.
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Nasal hyperreactivity as a IR selection-criterion
Various stimuli have been used to try to discriminate IR patients from nor-
mal controls. Nasal hyperreactivity to non-specific stimuli is a common and
characteristic feature of patients with chronic rhinitis. Hyperreactivity only
describes the increased reactivity of the nasal mucosa to ‘nonspecific’stimuli
such as smoke, strong odors and other irritants but does not point to any
cause of the disease. In addition, patients with allergic rhinitis usually com-
plain of hyperreactivity to nonallergic stimuli, obviously as a direct result of
allergic inflammation. Until now, the most common diagnostic test for meas-
uring nasal hyperreactivity was intranasal histamine provocation (37). Hista-
mine provocations in allergic rhinitis and asthma are proven to be a good
test for hyperreactivity.
Histamine provocation, however, fails to differentiate between patients with
IR and control subjects (38, 39). It has been shown that methacholine is able
to discriminate IR patients with persistent rhinorrhea from controls but not
IR patients with blockage as their main symptom (37). Also IR patients can-
not be characterised by increased responsiveness to capsaicin provoca-
tion(40).
Cold dry air (CDA) provocation as an effective tool in quantifying the
secretory response of hyperreactivity in persons susceptible to CDA was first
published by the Baltimore group (38, 41). The Rotterdam group subsequently
proposed a new standardised intranasal CDA provocation method, which is
able to make a reasonable distinction between IR patients and controls (39).
This new standardised intranasal CDA provocation resulted in increased
mucus production and nasal blockage in a dose-dependent manner in patients
Table 4. Exclusion criteria for IR
Positive allergy test (specific serum IgE, skin prick test, etc.)
Smoking (in the previous 6 months)
Nasal polyps or a history of nasal polyps.
Significant anatomical abnormalities affecting nasal function.
Nasal or paranasal sinus infection (abnormal sinus X-ray).
Pregnancy or lactation
Inability of the patient to stop taking medication affecting nasal function.
Beneficial effect of nasal corticosteroid spray (probably NARES patient)
18
with IR but not in control subjects. Sneezing did not occur. The reproducibility,
sensitivity and specificity of this CDA provocation gives us a useful diagnostic
tool in IR patients and the possibility to monitor treatment effect (39).
CONSIDERATIONS ON POSSIBLE PATHOPHYSIOLOGIC
MECHANISMS
In spite of trying to form an IR patient group as homogenous and uniform as
possible it still has to be anticipated that IR is a cumulation of different
pathophysiological entities. With the limited data available at the moment,
we will speculate which pathophysiological mechanisms might play a role
in IR. Whether the roles of these mechanisms are major or minor and which
are important for many or few patients with IR has to be further elucidated.
Chronic inflammatory disorder
The proposed pathophysiological mechanisms for IR include a chronic in-
flammatory disorder of antigenic (local allergy) or neurogenic nature (42-
45). A pivotal characteristic in the pathophysiological concept of inflamma-
tion is an influx of inflammatory cells in the affected tissue. In symptomatic
allergic rhinitis patients, an increase of inflammatory cells has been observed
in the nasal mucosa and this increase is positively correlated to nasal com-
plaints (46-48).
In a nasal biopsy study (35) we did not found any significant difference for
nasal mucosal lymphocytes, antigen-presenting cells, eosinophils,
macrophages, monocytes, mast cells and other IgE-positive cells between
IR patients and controls. This contrasts with a recent study of Powe et al.
who found significantly more nasal mucosa mast cells and eosinophils in a
group of IR (and allergic rhinitis) patients compared to a group of normal
individuals (25). They examined whole, full-length, full-thickness concha in-
ferior specimens resected under general anaesthesia.
The difference in study outcome may be explained by a more severe pathol-
ogy in the IR group of Powe et al. warranting total turbinectomy. Another
explanation could be the difference in biopsy size (average surface area of
1.6 mm2 in our studies). Nasal cellular infiltrates show a focal localisation of
cell populations which can be better averaged in larger biopsies.
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It may also be the case that our IR patient group contains significantly fewer
NARES patients (2 of the 65) compared to the patient group studied by Powe
et al. The reason for this could be the fact that a Dutch rhinitis patient will
not be sent to the ENT department before being treated with local
corticosteroids by his or her general practitioner (49). In addition, as might
be expected, it seems that NARES patients and or patients with an occult
local allergy form an IR subgroup which responds well to nasal corticosteroids
(29).
In two other studies, we failed to ascertain a relation between the number of
immunocompetent cells and nasal complaints in IR patients (23, 50). A sig-
nificant reduction of immunocompetent cells in the nasal mucosa of IR pa-
tients treated with nasal steroids (fluticasone aqueous nasal spray) was not
accompanied by a reduction in nasal complaints (23) and, inversely, a sig-
nificant reduction in nasal complaints in a group of IR patients treated with
topical capsaicin aqueous nasal spray was not accompanied by a reduction
in the numbers of inflammatory cells (50).
In a placebo controlled study Gerth van Wijk did not find a therapeutic effect
for capsaicin in a group of perennial allergic rhinitis patients allergic to house
dust mite (51). The capsaicin treatment protocol in this study was identical to
the one used by Blom showing a significant and long-term reduction of
symptoms in a group of IR patients (50). It was speculated that allergic rhinitis
was not affected by capsaicin through domination of nasal inflammation,
whereas the efficacy of capsaicin in IR may be due to domination of the
peptidergic system in the absence of nasal inflammation (51).
Neurogenic mechanisms
The neural regulation of the upper airways is complex and consists of a number
of interacting nervous systems. Sensory, parasympathetic and sympathetic
nerves regulate epithelial, vascular and glandular processes in the nasal
mucosa. The anatomically defined sensory parasympathetic and sympathetic
neural systems contain heterogeneous populations of nerve fibres often
containing unique combinations of neurotransmitters and neuropeptides (34,
52).
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Parasympathetic / sympathetic neural dysbalans
In 1959 Malcomson stated that IR was caused by an autonomic dysbalans
(53). Normally, base line sympathetic tone provides a constant alpha and
beta adrenergic receptor stimulation (54). The marked alpha-1 predominance
in nasal blood vessels leads to vasoconstriction (55). Underactivity of the
sympathetic nervous system leads to nasal obstruction (56). Parasympathetic
effects on blood vessels are minimal under basal conditions. Stimulation of
cholinergic nerves leads to hypersecretion and dilatation of mainly resist-
ance vessels (increase in nasal blood flow) and to some extent capacitance
vessels (decrease in nasal patency). Overactivity of the parasympathetic sys-
tem leads to rhinorrhea (56).
However, van Megen, in a group of 4 patients, was unable to show signifi-
cant differences in alpha-2, alpha-1 and beta-adrenoreceptors between con-
trols and vasomotor rhinitis patients (57).
On the other hand some data suggesting a sympathetic involvement in IR
has recently been published by the Liverpool group. Although the magnitude
between patients with IR and controls were small, patients with IR were
found to have an abnormal nasal response compared to controls after isometric
exercise (58) and after axiallary pressure (59). The specificity of these findings
compared to other forms of rhinitis however has to be confirmed.
Non-adrenergic non-cholinergic or peptidergic neural system
Due to extensive research in the seventies and eighties it was discovered that
perivascular and intra-epithelial nonadrenergic noncholinergic (NANC), sen-
sory nerve fibres contain neuropeptides (including VIP, substance P (SP),
calcitonin gene related peptide (CGRP), id.) which were demonstrated in the
nasal mucosa of various mammals including man (60, 61). The actions of
these neuropeptides are limited by degradation by neutral endopeptidase (62).
These neuropeptides are locally released from peptidergic neurons (anti-
dromic release), mainly unmyelinated sensory C-fibres, in the nasal mucosa
after activation by unspecific stimuli, and can be responsible for the symp-
toms of IR (63-65). Stimulation can be induced by inflammatory mediators,
like histamine and bradykinin but also by a number of inhaled irritants like
nicotine, cigarette smoke, formaldehyde and capsaicin (66-68).
The unmyelinated sensory c-fibres or ‘pain receptors’ are specifically sensi-
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tive to capsaicin (8-methyl-N-vanillyl-6-nonenamide), the pungent agent of
hot red pepper (69, 70). Nasal capsaicin provocation results in rhinorrhea,
nasal blockage and sneezing (52). This sensory neural stimulation may pro-
duce these effects either through an orthodromic, central neural reflex, asso-
ciated with efferent, predominantly parasympathetic, neurotransmission, and
or via an anti-dromic, afferent, local release of neuropeptides from sensory
neurons (71) (Figure 2). Repeated applications of capsaicin, however, lead
to desensitisation and even degeneration of peptidergic unmyelinated sensory
C-fibres (72, 73).
Therefore the hypothesis, suggested  among others by Wolf (74), that a hyper-
active non-adrenergic non-cholinergic peptidergic neural system is the un-
derlying pathophysiology in IR, may offer an explanation for the beneficial
effect of intranasal capsaicin with these patients.
This hypothesis was corroborated by Lacroix, who reported an increased
concentration of neuropeptides in a group of chronic IR patients (65), im-
provement of symptoms by local treatment of capsaicin giving a 50% reduc-
tion in CGRP-Li content in nasal biopsies (75), and a correlation between
symptom intensity and CGRP-Li concentration in nasal mucosa (76). Several
studies have been published showing a therapeutic effect in IR patients for
repeated topical applications of capsaicin (77-79).
However, the mechanism explaining this therapeutic effect remains for the
greater part unclear. In spite of the CGRP-Li reduction found by Lacroix we
did not find any significant difference in pan-neurogenic staining of nasal
mucosa using neurofilament and synaptophysine between capsaicin and pla-
cebo treated patients 2 weeks, 3 months and 9 months after therapy although
there was a significant therapeutic effect measured with visual analogue scale
(VAS) (50). Also Wolf was unable to show a reduction of NANC-fibres in
the nasal mucosa in IR patients after successful capsaicin treatment  (77). He
suggested capsaicin receptor blockage as a possible explanation for the cap-
saicin treatment effect. Although sounding attractive it seems improbable that
capsaicin receptor blockage alone can result in the long lasting therapeutic
effect observed in IR patients.
These findings, however, do not discard the hypothesis of a hyperactive non-
adrenergic non-cholinergic peptidergic system, as the activity of this system
was not measured. A functional hyperactivity of this system, not captured by
22
histological changes, could still be the underlying pathophysiological process
in IR.
Hyper- or dysesthesia at the CNS level
Another possibility, raised by Sanico, is a hyper- or dysesthesia at the central
nervous system (CNS) level as an explanation for IR (34) (Figure 2). This
would explain the lack of changes/differences in cell counts and neurogenic
staining in the several studies mentioned above. According to this theory a
functional or numerical downregulation of the unmyelinated peptidergic
sensory C-fibres would also explain the therapeutic effect of intranasal
capsaicin application (34). One might speculate that CNS hyperesthesia is
induced by a vicious circle of environmental irritants and changes in
atmospheric conditions, perceived as an ever irritating stimulans at the CNS
level, and the protective responses hereupon like rhinorrhea, vascular
congestion and sneezing. Although sounding attractive, it will be hardly
impossible to prove due to the key role allocated to the CNS in this theory.
Nitric Oxide synthase
Recently Ruffoli, et al. reported a strong localisation of nitric oxide synthase
(using NADPH-diaphorase cytochemistry) in the vascular smooth muscle
cells of the cavernous sinuses in 7 IR patients compared to the nitric oxide
synthase localisation in unaffected subjects (80). In their article they
hypothesise that local, anti-dromic neuropeptide release of sensory fibres in
the nasal mucosa of IR patients could cause nitric oxide synthase induction
in vascular smooth muscle cells through a c-AMP dependent mechanism, giving
nasal congestion. However, no significant differences were found in
endothelial nitric oxide synthase localisation between IR patients and
Figure 2. Simplified scheme of autonomic and peptidergic innervation of the nasal mu-
cosa. Irritation initiates an afferent, sensory signal. After central processing this will lead
to an efferent, predominantly parasympathetic signal giving rise to increased secretion
and vasodilatation: the orthodromic reflex. The initial irritation also induces the local
release of neuropeptides (SP, CGRP, etc.) from sensory nerves in the nasal mucosa also
resulting in increased vasodilatation, vascular permeability and secretion: the antidromic
reflex.
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unaffected subjects. Although interesting, it is to early for definitive conclusions
about a possible role for nitric oxide synthase in the pathophysiology of IR.
TREATMENT MODALITIES
In general one can state that the less is known about a disease (and its
underlying pathophysiology) the more treatment options there are available.
This in particular counts for IR with a wide range of available therapies,
surgical as well as pharmacotherapeutical, all claiming partial success. With
the exception of rhinitis of the elderly where ipratropium bromid is the obvious
first treatment of choice (see above), there is no obvious best treatment or
first treatment to start with in nonallergic noninfectious rhinitis.
Topical or systemic sympathicomimetica
A topical sympathicomimeticum provides instant relief but only for a short
period. It should not be used for more than 1 week in view of the risk for
developing rhinitis medicamentosa (see above). Considering this it only has
a very limited role in the therapeutic arsenal of chronic IR. Systemic
sympathicomimetica, although widely used in some countries,  seem to have
many considerable side effects (81).
Topical steroids
In our view, a topical steroid aqueous spray once or bi daily, preferably
combined with nasal 0.9% saline douches, is the treatment of first choice in
IR (82). It should be tried for a minimum period of 6 weeks before treatment
evaluation should take place, for it can take a few weeks to reach the maxi-
mum treatment effect (83, 84). Often IR patients, referred by the general prac-
titioner to the second or third echelon due to treatment failure after short
time use of a topical steroid spray, react as yet favourable to topical steroid
spray using it for a longer period.
However, with the exception of  NARES patients who in general respond
well to a topical steroid spray (see above) we feel that for the rest of the
nonallergic noninfectious rhinitis patients topical steroids often do not provide
the same relief as they do in allergic rhinitis (23, 43).
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Antihistamines
Sneezing as a predominant complaint in nonallergic noninfectious rhinitis is
rare, but if present antihistamines can be prescribed, sometimes with good
results (1). Also in the case of extreme hyperreactivity antihistamines are
sometimes helpful, possibly because of a pathophysiologic role for mastcell
degranulation releasing histamine in these patients. Two double-blind pla-
cebo controlled trials have been published showing a therapeutic effect for
azelastine nasal spray in IR patients with nasal obstruction and or rhinorrhea
(85, 86). The precise mode of action (antihistaminic, antiinflammation, or
otherwise) remains to be elucidated (87).
The older antihistamines often also have some anticholinergic action possibly
contributing to the therapeutic effect.
Ipratropium bromid
Ipratropium bromid is an anticholinergic drug used mainly in the treatment
of asthma. Clinical studies using this drug as a nasal spray have shown it to
be effective in reducing the severity and duration of the rhinorrhea in
nonallergic noninfectious rhinitis (17, 88). It is therefore the first treatment
option in rhinitis of the elderly (see above).
Capsaicin
As mentioned before several studies have been published showing a
therapeutic effect in IR patients for repeated topical applications of capsaicin
(77-79). Although direct observations explaining the efficacy and working
mechanisms of capsaicin are lacking, it is the therapy of choice in IR patients
in our institutes when a minimum period of 6 weeks of treatment with a topical
steroid spray has proven unbeneficial in relieving symptoms. Of course, as
with other therapies for IR, not all patients will be cured but a great percentage
of patients (we feel circa 75%) will show a long lasting (more than one year)
relieve of symptoms. When IR symptoms return after a symptom free period
upon capsaicin therapy it is very worthwhile to treat these patients (after
careful examination excluding again all known causes of rhinitis) for a second
(or sometimes third) time with capsaicin for the favourable reaction to
capsaicin will most probably repeat itself (unpublished data). This was also
reported by Wolf (77).
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Surgery
Most authors feel that surgical therapy should only be considered for those
patients who fail to obtain symptomatic relief with medical therapy (20, 56,
82). Surgical procedures for nonallergic noninfectious rhinitis aim to either
modify the size of the inferior turbinate or to denervate the nose of its
autonomic supply. Turbinate reduction can be a valuable alternative when
medical therapy fails. The surgical scalpel, chemical sclerosing solutions,
electrocautery, cryosurgery, snake venom and laser surgery have all been
reported to diminish obstruction complaints (89-93). The duration of
effectiveness reported varies from 6 months to several years (55). Golding-
Wood described the effect of vidian neurectomy (94, 95). This procedure is
effective in relieving excessive secretion but not so much the obstruction.
Both preganglionic parasympathetic and sympathetic fibres are interrupted.
Grote concluded that vidian neurectomy was not the panacea it was claimed
to be, since renervation would occur (96). This was corroborated by several
authors (97, 98).
CONCLUSION
Although the percentage of patients with nonallergic noninfectious rhinitis
with a known cause has increased the last decades, still about 50% of the
patients with a nonallergic noninfectious rhinitis have to be classified as
suffering from IR. Specific immunological, clinical and sometimes radiological
and functional tests are required to distinguish known causes. Research to the
underlying pathophysiology of IR has moved from autonomic neural dysbalans
to inflammatory disorders (local allergy), the NANC peptidergic neural system
(with or without nitric oxide synthase induction in vascular smooth muscle
cells) and central neural hyperesthesia, still without convincing solid ground
or proof. It can be expected that in the next future some more explanatory
pathophysiologic mechanisms for nonallergic noninfectious rhinitis will be
found, doing justice to the idea that the diagnosis IR is still a ‘melting pot’ of
several pathophysiological conditions. Hopefully the future unravelling of
this intriguing disease will lead to more specific and may-be better treatment
options.
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Chapter II
Aim of the study
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The introduction to this thesis summarizes the literature for known causes of
nonallergic noninfectious rhinitis and possible treatments. Also possible
pathophysiological mechanisms of idiopathic rhinitis are discussed.
The fact that still about 50% of the patients with a nonallergic noninfectious
rhinitis have to be classified as suffering from idiopathic rhinitis, or rather e
causa ignota, is a continuing and frustrating burden for almost every clinicaly
active ENT specialist and allergologist. This, combined with the limited and
frequently insufficient treatment options currently available, was the guideline
for the research described in this thesis.
The research questions addressed in this thesis are:
1 Is local, intranasal capsaicin a safe and effective therapy in idiopathic
rhinitis?
2 Is it possible to develop an effective capsaicin treatment regimen that
is more patient and physician friendly compared with those known from
literature?
3 Is idiopathic rhinitis a chronic inflammatory disorder?
4 Do inflammatory cells and or sensory neurons play a role in the
pathophysiology of idiopathic rhinitis?
5 What is the direct mode of action of local capsaicin on nasal
mucosa cell counts and neurogenic staining.
The first two questions are addressed in chapter III and IV by two double-
blind placebo controlled trials evaluating the treatment effect of intranasal
capsaicin against placebo for idiopathic rhinitis patients. In chapter IV specific
attention is paid to safety data and olfactory function during and after intranasal
capsaicin treatment.
The third and fourth question are addressed in chapter V and VI. In chapter V
mucosal inflammatory cell densities in nasal biopsies of idiopathic rhinitis
patients are compared with nasal biopsies from healthy controls. The
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involvement of inflammatory effector cells, the possibility of local allergy
and possible neurogenically induced mast cell degranulation are studied. In
chapter 5 the long term effects of intranasal capsaicin on the cellular
homeostasis and overall neurogenic staining of the nasal mucosa are studied
in a double-blind placebo controlled fashion.
The last question is addressed to in chapter VII with a double-blind placebo
controlled biopsy study comparing the effect of intranasal capsaicin against
placebo on nasal mucosa cellular homeostasis and neurogenic staining 15
minutes and 1 hour after provocation.
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CHAPTER III
Intranasal capsaicin is efficacious in nonallergic, noninfectious perennial
rhinitis. A placebo-controlled study.
 H.M. Blom, J.B. van Rijswijk, I.M. Garrelds, P.G.H. Mulder, T.
Timmermans and R. Gerth van Wijk.
Clinical and Experimental Allergy, 1997, volume 27, pp 796-801
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ABSTRACT
Background: Several authors described capsaicin, the pungent substance in
red pepper, as an efficacious therapy for idiopathic rhinitis (IR). Repeated
capsaicin application induces peptide depletion and specific degeneration
of the unmyelinated sensory C-fibres in the nasal mucosa.
Methods: We performed a placebo-controlled (NaCl 0.9%) study with 25 IR
patients. Daily record charts and visual analogue scales (VAS) were used for
clinical evaluation. Nasal lavages were obtained before, during, and after
treatment.
Results: There was a significant and long-term reduction in the VAS scores
in the capsaicin group. No significant difference was found between the pla-
cebo and capsaicin treated groups for the mean group concentrations of
leukotriene (LT) C4/D4/E4, prostaglandin D2 (PGD2), and tryptase. The levels
of mast cell mediators, tryptase and PGD2, and leukotrienes, mediators de-
rived from a variety of inflammatory cells, were low at baseline and compa-
rable with levels observed in nasal lavages obtained from normals.
Conclusion: As involvement of inflammation could not be demonstrated, it
is not surprising that capsaicin has no effect on inflammatory mediators.
This suggests that inflammatory cells do not play a major part in the
pathogenesis of IR.
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INTRODUCTION
The knowledge of idiopathic rhinitis (IR) or vasomotor rhinitis is limited.
This condition is unrelated to allergy, infection, structural lesions and / or
other systemic diseases (1). The diagnosis is made by exclusion. Patients
within this classification may complain of symptoms such as sneezing, wa-
tery rhinorrhoea and/or nasal obstruction. Treatment of this condition is more
difficult than that of allergic rhinitis, a disease which can be relieved by use
of antihistamines and nasal steroids.
The pathophysiology of non-allergic rhinitis is largely unknown (1). Several
hypotheses have been put forward. A subgroup of patients may react to cold
dry air with release of inflammatory mediators from mast cells involving a
non-IgE-dependent mechanism (2). Inflammatory cells appears to play a
minor part in the vast majority of patients (3). However, Knani reported a
significant increase in tryptase levels, and increased levels of LTC4 and PGD2
in nasal lavage in symptomatic IR patients vs control subjects (4). Neuro-
genic mechanisms may be important since some patients, who react with
watery discharge to spices and change of temperature, may benefit from use
of anticholinergics (5).
Lacroix has shown that repetitive administration of capsaicin - the pungent
agent in hot pepper - reduces nasal symptoms in patients with a rhinosinusitis,
for which they underwent sinus surgery, or patients suffering from a drug-
induced rhinitis (6). This reduction is accompanied by a decrease in positive
immunoreactivity to calcitonin gene-related peptide (CGRP) in nasal biop-
sies. This observation is consistent with the observation that capsaicin in-
duces peptide depletion and specific degeneration of the sensory C-fibres in
the nasal mucosa of rodents (7). Several studies have been published show-
ing that capsaicin desensitization might be an important therapeutic modal-
ity in IR (6,8-10). However, no placebo-controlled studies have been per-
formed. Moreover, the reported studies lack well-defined criteria for having
IR, with the risk of heterogeneity of the patients used.
The purpose of this study was to evaluate capsaicin treatment in a placebo-
controlled fashion using a homogeneous group of well-characterized patients
suffering from IR. Second, by measuring mediators of inflammation in nasal
lavage fluid, we investigated the involvement of inflammation in IR and the
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possible modulation by capsaicin.
METHODS
Subjects
Patients were admitted to the study if they had a history of nasal complaints
such as nasal obstruction, sneezing, and rhinorrhoea for a period of over 1
year which could not be attributed to allergic rhinitis, nasal or paranasal
sinus infection, anatomical disorders affecting nasal function, pregnancy or
lactation and / or systemic disorders (Table 1). They were non-smokers not
using medication affecting nasal function. Patients with nasal polyps were
excluded, since they may belong to a different pathophysiological group and
their polyps may contribute to a higher symptom score for nasal blockage
and/or rhinorrhoea. Thirty-five patients, with the diagnosis of IR, scored their
nasal complaints for a period of 2 weeks using a daily record chart (DRC)
(Table 2) (11). In affected patients periods of either nasal discharge, and/or
sneezing and/or congestion had to persist for an average of at least 1 h per
Table 1.
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day for at least 5 days during a period of 14 days. Coughing and coloured
mucus production were used as indicators of upper airway infection and
thus used as exclusion criterion. The duration of complaints during the day
was used as the prime criterion for further study. Twenty-five of the 35 patients
were found eligible for our study and participated under conditions of
informed consent (male/female: 16/9); mean age was 36 years (18-60).
Procedures were approved by the local Medical Ethics Committee.
Study design
Patients were randomized and treated with placebo (11 persons) or capsaicin
(14 persons) as depicted in Fig. 1a. This study was performed in a double-
blind placebo-controlled fashion. Three applications of
xylometazolinehydrochloride 0.1% (Otrivin (1 mg/mL Zyma, Breda,
Holland), nebulizator) were given for decongestion in each nostril. The nasal
airway was anesthetized by three applications (10 mg/puff) of lidocainebase
(100 mg/mL) (Xylocaine 10% spray (Astra, Rijswijk, Holland)) in each
nostril. To ensure good anaesthesia a pause of 15 min was introduced. Lips,
columella, and philtrum were covered with a petrolatum/lanolin/glycerin
salve. Capsaicin test puff was done in an exhaust hood to avoid eye irritation.
Patients were instructed to inhale deeply before, hold their breath during and
to exhale after substance application. The capsaicin solution (0.1 mmol/L)
Table 2.
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consisted of pelargonic acid vanillylamide (Fluka, Buchs, Germany) dissolved
in 3 mL alcohol (96%) and diluted in 1 L NaCl solution (0.9%) (Wolf, pers.
comm.). For ‘placebo therapy’ we used NaCl solution (0.9%). During
provocation 0.5 mL solution was sprayed in each nostril (0.15 mg capsaicin).
Blood and urine samples were taken during visits 1 and 9 (Table 1) to monitor
changes during therapy. At every visit the subjects rated overall nasal
symptoms since the last visit on a visual analogue scale (VAS) (0-10 cm, 0
represented absence of symptoms and 10 represented high intensity of
symptoms). DRC scoring was continued until 2 weeks after treatment. Nasal
lavage was performed according to the method of Greiff (12), using a modified
nasal pool device. Experience with nasal lavage has been obtained in several
studies (13). Nasal lavage was performed (Fig. 1b) with 14 mL saline,
preheated to 37 °C. Seven millilitres of saline were instilled into each nostril.
After 10 s, the lavage fluid was expelled and collected in tubes, stored on ice
and centrifuged for 10 min at 400 ×g. The supernatant was stored at -20 °C
until analysis.
Figure 1.
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Mediator assays
The levels of leukotriene (LT) C4/D4/E4 and prostaglandin (PG) D2 were
measured by Biotrak and Radioimmunoassay (RIA), respectively
(Amersham, UK). The limits of sensitivity of the assays were (almost equal
to) 10 pg/mL for both assays. Cross reactivity of LTC4/D4/E4 assay: LTC4
(100%), LTD4 (100%), LTE4 (70%), LTB4 (0.4%) and prostaglandins (<
0.006%); PGD2 assay: PGD2 (100%), PGJ2 (7%), TxB2 (0.3%),
PGF2(alpha) (0.04%) and other prostaglandins (< 0.02%).
Tryptase was determined by RIA according to the manufacturer’s instructions
(Pharmacia, Uppsala, Sweden). The detection limit was 0.5 mU/mL.
Crossreactivity for heparin (< 0.01%) (14).
Statistical analysis
VAS data during treatment were analysed using a repeated measures analy-
sis of variance. In the model, time was included as a quantitative variable;
the interaction between time and treatment group was also included. Hence,
a difference in time trend between the two treatment groups can be esti-
mated and tested. The within-subject (co)variance matrix of the residuals is
supposed to be unstructured. Leukotrienes, prostaglandin D2, and tryptase
are analysed after log transformation.
Measurements after treatment (visits 9, 10, and 11) were analysed separately
as changes from baseline using t-tests, between groups (unpaired) as well as
within groups (paired). DRC data are summarized as within patient averages
over 2-week periods: a first period before randomization/treatment, a second
period after randomization (during therapy) and a third period after cessation
of treatment. Between groups differences are tested using the Mann-Whitney
U-test. P-values < 0.05 were considered significant.
RESULTS
The application of Xylocaine spray in the nasal airway was immediately
followed by a painful sensation that was described by all subjects as most
unpleasant. Patients did not complain of irritation of nose and lips during or
after capsaicin/placebo application.
46
One of the 14 capsaicin patients could not continue after three capsaicin
applications because of influenza with fever.
Symptom scores
DRC
The mean score (± standard error of the mean) on the DRC of the included
patients was 2.0 (± 0.049) for blockage, 1.4 (± 0.044) for clear nasal dis-
charge, and 1.5 (± 0.033) for sneezing before therapy. No significant differ-
ence was found for the individual symptoms as well as the mean sumscore
before, during or after therapy.
VAS
The mean of VAS is shown in Fig. 2. There was no significant difference
between the groups in the VAS score before treatment. During treatment a
smaller trend with time (-0.40 per two days) was seen in the capsaicin group
than in the placebo group (+ 0.019 per two days), the difference being
significant (P = 0.0007). At visits 9, 10 and 11 the difference between the
groups remained significant. Also, the difference from baseline remained
Fig. 2. The mean of the symptom score measured on a V.A.S. (0-10 cm, 0 represented
absence of symptoms and 10 severe intensity of symptoms) for nasal complaints. Y error
bars indicate 2.07 SE.  black up pointing small triangle: Capsaicin. star (upper curve):
Placebo.
47
significant within the capsaicin group from visit 9 onwards. This was not the
case in the placebo group (Fig. 2).
Nasal lavage
The median return, of the 14 mL NaCl instilled, was 10 mL. The mean base-
line levels (± standard error of the mean) of tryptase, LTC4/D4/E4, and PGD2
were 1.98 (± 0.422) mU/mL, 7.70 (± 3.10) pg/mL, and 16.2 (± 2.00) pg/mL,
respectively, in the nasal lavage fluid of the treated group.
The mean baseline levels (± standard deviation) of tryptase, LTC4/D4/E4,
and PGD2 were 2.09 (± 0.611) mU/mL, 2.62 (± 1.12) pg/mL, and 16.4 (±
2.85) pg/mL, respectively, in the nasal lavage fluid of the placebo group.
During treatment no significant difference in time trend between the two groups
was found for the concentrations of tryptase, LTC4/D4/E4, and prostaglandin
D2 in the nasal lavage fluid. At visits 9, 10 and 11 no significant changes from
baseline or significant differences between the groups were found neither.
Safety data
None of the patients had a relevant change of blood and/or urine chemistry
outside the normal range.
DISCUSSION
There is a dearth of information regarding the pathophysiology of IR. The
limited understanding of this condition hampers the development of thera-
peutic modalities. An imbalance in the non-adrenergic, non-cholinergic
peptidergic neuronal system has been proposed as the underlying mecha-
nism of IR (15). Treatment with capsaicin may fit in with this hypothesis
(16). This study showed that seven treatments in a 14-day period amelio-
rated symptoms during a follow-up of 9 months. It is possible that reduction
of symptoms will last longer; however, we feel that it is unethical to main-
tain a placebo-treatment for many months, so we ended the trial after 9 months
of follow-up. This long-term placebo-controlled study confirmed the effi-
cacy and safety observations made during open uncontrolled studies (6,8-
10).
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The study has several limitations. The study was designed in a placebo-con-
trolled double-blind fashion. However, we did not expect that we could blind
the treatment for the patients, as this was considered impossible by several
authors. In contrast to our expectations patients complained severely about
the XylocaineR spray. Therefore, they were not able to discriminate between
the active and the placebo substance. Furthermore the immediate respons to
treatment did not permit us to discriminate between patients receiving cap-
saicin or placebo.
Second, since we used saline as placebo treatment rather than the solution
used for dissolving capsaicin (which contained saline with 0.3% alcohol
96%), we cannot exclude the possibility that an effect of alcohol biased the
therapeutic efficacy of capsaicin. It is, however, unlikely that instillation of
these minute quantities of alcohol will induce a significant reduction in nasal
symptoms during 9 months. Moreover, saline containing a fivefold dose of
1.5% alcohol has no effect on nasal conductance (17).
Finally we encountered a discrepancy between the reduction in VAS score
and the absence of effect on DRC, which might be explained by the differ-
ence in nature between the scoring methods. The VAS scores the severity of
the complaints whilst the DRC scores the duration of the complaints.
Furthermore, as the study proceeded patients compliance (in filling in the
DRC) seemed to grow less, since scoring the DRC is a time-consuming and
daily returning task. At the end of the trial some patients even reported that
they had filled in their DRCs all at once just prior to their hospital visit.
In contrast, the VAS score is a quick and easy method for the patient. Also
the fact that the placebo group showed no evidence of improvement in the
VAS combined with the finding that the duration of the treatment’s effect is
quite impressive and consistent with what all the previous uncontrolled studies
have suggested (6,8-10), we feel the VAS is more reliable than the DRC.
In animals capsaicin stimulates sensory C-fibres with the resultant release of
substance P (SP) (7,18) and calcitonin gene related peptide (CGRP) (19).
However, after several stimulations this is followed by depletion of these
fibres and results in desensitization to capsaicin and other stimuli (16). As
tachykinins (20) and capsaicin (21) induce the recruitment of inflammatory
cells in the nose in allergic rhinitis and SP releases histamine and TNF(alpha)
from peritoneal mast cells in animals (22), capsaicin may modulate inflam-
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mation of the nasal mucosa. The levels of tryptase, PGD2, and leukotrienes,
mediators derived from several inflammatory cells such as eosinophils,
basophils, and mast cells (23,24), were low at baseline and comparable with
levels observed in nasal lavages obtained from normals (C. de Graaf-in ‘t
Veld, pers. comm.). This contrasts with the results presented by Knani (4)
However, six out of 14 patients in Knani’s study showed a prominent eosi-
nophilia in nasal secretions and may have been NARES patients. Our data
concord with the findings of Roche, however this paper describes the results
in asymptomatic patients. As involvement of inflammation could not be dem-
onstrated, it is not surprising that capsaicin has no effect on inflammatory
mediators. Perhaps the absence of inflammation, also demonstrated in a re-
cent study (3), is an explanation of the moderate efficacy of nasal steroids in
non-allergic rhinitis.
To conclude, capsaicin is an efficacious substance in the treatment of IR. In
our placebo-controlled study a therapeutical effect lasted more than 9 months.
No effect was found on inflammatory mediators. No adverse side-effects
were noted.
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ABSTRACT
Background: In a recent study, we showed that intranasal capsaicin spray
gives a significant and long-term reduction of symptoms in nonallergic non-
infectious perennial rhinitis patients. However, in daily practice, the studied
application regimen proved to be impractical because of the large number of
visits required in a short period of time. In the present study, we conducted a
double-blind double-dummy parallel groups trial to determine whether a more
practical capsaicin application schedule is equally effective.
Methods: Thirty patients were randomized into two different treatment regi-
mens: one group received capsaicin five times the first day at one-hour inter-
vals. This was followed by a placebo dummy once every second or third day
for a total of five treatments 2 weeks after the capsaicin application (group
A). The other group (B) received the placebo dummy five times on the first
day followed by capsaicin once every second or third day for a total of five
treatments 2 weeks after the placebo application.
Results: The visual analogue scale scores for overall nasal symptoms,
rhinorrhea and nasal blockage showed significant decrease after the start of
treatment in both groups, with a significantly  steeper decrease in group A. A
significant reduction in cold dry air dose responsiveness was also found up
to 9 months after therapy in both groups, reflecting a decrease in nasal
hyperreactivity. No significant changes in safety data (smell, blood pressure,
heart rate) were found.
Conclusions: We conclude that intranasal capsaicin seems safe to use and
that five treatments of capsaicin on a single day is at least as effective as five
treatments of capsaicin in 2 weeks.
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INTRODUCTION
Perennial rhinitis is a common disorder causing significant morbidity. Chronic
rhinitis can be due to common factors such as mechanical obstruction, al-
lergy or less common factors such as xylometazoline abuse or cystic fibro-
sis. But there are several types of chronic rhinitis of which the pathophysiol-
ogy is not yet fully elucidated. Syndromes of chronic rhinitis with an un-
known aetiology include nonallergic noninfectious perennial rhinitis, for-
merly referred to by us as NANIPER. In accordance with the ‘’World Health
Organisation Initiative, Allergic Rhinitis and its Impact on Asthma’’ (1), hence-
forth we will be using the term idiopathic rhinitis (IR) to describe this pa-
thology. IR, formerly also called vasomotor rhinitis, is a diagnosis of exclu-
sion and is given to patients who suffer from perennial nasal congestion,
rhinorrhea and/or sneezing with no identifiable aetiology. IR is unrelated to
allergy, infection, structural lesions, polyposis and other systemic diseases
(2). Patients with nonallergic rhinitis with eosinophilia syndrome (NARES)
form another subgroup of IR patients. They have significant mucosal eosi-
nophilia (a nasal smear with more than 25% eosinophils (3)) and respond
well to nasal corticoster oids (4). In previous studies, we found hardly any
patients with NARES in our IR patient groups, probably because we only
selected IR patients in whom no therapeutic effect had been achieved with
nasal corticosteroids (5, 6).
The population incidence of IR is estimated at 2-4 %(1). The impact on the
quality of life of patients suffering from chronic rhinitis is significant, a fact
that is often underestimated and neglected (7). In many patients, treatment
with anti-histamines, nasal steroids or even nasal surgery is not beneficial
(2).
The pathophysiology of IR is largely unknown. Several hypotheses have been
put forward. Inflammatory cells appear to play a minor part in the vast ma-
jority of patients (5, 6). It is assumed that neurogenic mechanisms play an
important role (8). Neuropeptides (CGRP, SP, etc.) are released from
peptidergic neurons in the nasal mucosa after activation by unspecific stimuli,
and can be responsible for the symptoms of IR(9-11). Several studies have
been published showing a therapeutic effect in IR patients for repeated topi-
cal applications of capsaicin (12-15). Capsaicin, the pungent agent in hot
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pepper, is known for its degeneration/desensitization effect on peptidergic
sensory C-fibres, possibly explaining its therapeutic effect (16, 17).
In a recent paper, we showed that repeated administration of capsaicin in a
double blind placebo-controlled trial led to a significant and long-term re-
duction of symptoms (15). That study showed that intranasal capsaicin appli-
cation once every second or third day for a total of 7 days has a significant,
long lasting beneficial effect compared with placebo. However, in daily prac-
tice, the studied application regimen proves to be unpractical for both pa-
tient and physician because of the large number of visits required in a short
period of time.
The purpose of the present study was to conduct a double-blind double-dummy
parallel groups trial to determine whether a more practical capsaicin
application schedule is equally effective. Furthermore, we collected more
safety data (blood pressure, heart rate) and paid specific attention to nasal
capsaicin sensitivity, mucosal sensibility and olfactory function before and
after therapy.
MATERIALS AND METHODS
Subjects
Patients were admitted to the study if they had a history of nasal complaints
such as nasal obstruction, sneezing and/or rhinorrhea for a period of over 1
year, which could not be attributed to allergic, nasal or paranasal infection,
anatomical disorders affecting nasal function, pregnancy or lactation and/or
systemic disorders (Table 1). They had to have used a nasal corticosteroid
spray for at least 6 weeks without any beneficial effect on their nasal symp-
toms. They were non-smokers not using medication affecting nasal func-
tion. All patients underwent nasendoscopy and patients with nasal polyps
were excluded.
Patients with a diagnosis of IR scored their nasal complaints for a period of
2 weeks using a daily record chart (DRC) (Table 2). They were included in
the study if periods of either clear nasal discharge, and/or sneezing and/or
congestion persisted for an average of at least 1 h a day for at least 5 days
during a period of 14 days (18). Thirty patients participated under conditions
of informed consent (male/female: 14/16); mean age was 36 years (16 – 65
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Table 1. Inclusion and exclusion criteria.
Inclusion criteria
Age between 16 and 65 years.
Negative Phadiatop (Pharmacia, Uppsala, Sweden)
Symptoms for more than 1 year.
Periods of nasal discharge, sneezing and congestion for an average of at least 1 h per day
for at least 5 days during a period of 14 days.
No beneficial effect of nasal corticosteroid spray (for a period of at least 6 weeks)
Exclusion criteria
Use of systemic or inhaled corticosteroids in the previous month.
Use of inhaled sodium cromoglycate or nedocromil sodium in the previous month.
Use of astemizole in the previous month.
Inability of the patient to stop taking medication affecting nasal function.
A serious and/or unstable disease.
Smoking (in the previous 6 months)
Nasal surgery in the previous 6 weeks.
Nasal polyps or a history of nasal polyps.
Significant anatomical abnormalities affecting nasal function.
Nasal or paranasal sinus infection (abnormal sinus X-ray).
Pregnancy or lactation
years). Procedures were approved by the local Medical Ethics Committee.
Study design
This study was performed in a double-blind  randomized fashion. Patients
were randomized 1 : 1 either for group A or for group B. For this purpose a
computer generated randomization list was prepared in blocks of 8 randomly
permuted allocations. On the basis of this list the double-blind medication
was prepared by the local pharmacist. Patients in group A were first treated
with capsaicin five times on a single day at 1-h intervals. After 2 weeks, they
received a total of five treatments with dummy placebo once every second
or third day. Patients of group B first received dummy placebo five times on
a single day at 1-h intervals. This was followed 2 weeks later by a total of
five treatments with capsaicin once every second or third day. The dummy
placebos serve to ensure blindness of the study. The study design is shown in
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Fig. 1.
Each application of capsaicin or placebo was preceded by three applications
of xylometzoline-hydrochloride 0.1% [Otrivin nebulisator (1mg/ml Zyma,
Breda, Holland)] in each nostril for decongestion. The nasal mucosa was
then anaesthetized by three applications (10mg/puff) of lidocaine base
[100mg/ml, Xylocaine 10% spray (Astra, Rijswijk, Holland)] in each nos-
tril. To ensure good anaesthesia a pause of 15 min was introduced. The lips,
columella and philtrum were covered with a petrolatum/ lanolin/ glycerine
salve. The capsaicin solution (0.1 mmol/l) consisted of 30.3 mg pelargonic
acid vanillylamide dissolved in 3 ml alcohol (96%) and diluted in 1 l NaCl
Table 2. Design of the daily record chart for defining nasal symptoms in IR patients.
Possible scores on the daily record chart
Nasal blockage:
(not being able to breathe freely through the
nose)
Clear nasal discharge: (runny nose)
0 = absent
1 = between 0-1h per half day
2 = between 1-2 h per half day
3 = more than 2 h per half day
Sneezing
Coughing
0 = absent
1 = less than 5 periods per half day
2 = between 5-10 periods per half day
3 = more than 10 periods per half day
Green/Yellow mucus production: 0 = absent
1 = present
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solution (0.9%). As placebo, we used the capsaicin solvent only. During
provocation, 0.27 ml of solution (three applications) was sprayed into each
nostril with a metered nasal spray (0.09 ml per actuation, coefficient of vari-
ation 4%).
At every visit, the subjects rated the following four nasal symptoms during
the last 3 days on four separate visual analogue scales (VAS) (0-10 cm, 0 cm
represented an absence of symptoms and 10 cm represented highest intensity
of symptoms): overall nasal symptoms, rhinorrhea, nasal obstruction and
sneezing. DRC scoring was continued during administration with capsaicin
and placebo until 4 weeks after the last treatment and 1 week before every
follow-up visit thereafter.
Olfactory function
Olfactory function was measured before and after treatment using the
University of Pennsylvania Smell Identification Test (UPSIT)(19).
Cold dry air provocation / nasal reactivity
Nasal reactivity (nasal patency, mucus production, and sneezing) was
measured using standardized cold dry air provocation (CDA) before and after
therapy. The dose steps for cold dry air were 12.5, 25, 50, 100, 200 and 400
l, comprising of a first step of 12.5 l/min and other steps of 25 l/min at,
respectively, 1, 1, 2, 4, 8 and 16 minutes. The –10 oC air leaving the respiratory
heat exchanger (Jaeger GmbH, Wurzburg, Germany) had a relative humidity
of < 10 % and entered the nasal cavity by means of a specially designed nose
cap (Respricare, The Hague, The Netherlands). As soon as a threshold dose
resulting in 40% reduction of nasal patency and/or 0.5 g mucus production
(cut-off lines) was reached, the provocation series was stopped (20).
Nasal patency: acoustic rhinometry and PNIF
Nasal patency was studied before, during and after therapy. The acoustic
rhinometer Rhin2100 (RhinoMetrics, Denmark) was used to measure the
first two minimal cross-sectional areas (MCA1 and MCA2) using contoured
nose-adaptors. To reduce variability, three replicate measurements were done
and the mean of these measurements (MMCA1 and MMCA2) was used for
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further  analysis.
Nasal patency was also studied on the basis of peak nasal inspiratory flow
(PNIF) before, during and after therapy. On each occasion, three replicate
PNIF measurements were done and the best one was used for further
comparison/statistics.
Capsaicin sensitivity
Capsaicin sensitivity was measured before, during and after therapy by
spraying capsaicin solution and placebo into both nostrils in a random order
and asking the patient to point out which of the applications caused a pungent
sensation (to discriminate the capsaicin solution from the placebo). Starting
at 10-8 M, the capsaicin concentration was increased multiplicatively each
time by the cubic root of 10, until the patient correctly distinguished the
capsaicin solution from placebo three times in a row. This concentration
indicated capsaicin sensitivity.
Mucosal sensibility
To study mucosal sensibility before and after therapy we touched the patients’
nasal mucosa in a random order with a cotton wool stick (testing epicritic
sensibility) and a thin metal rod (testing protopathic sensibility) and asked
them to rate this sensation on a VAS (0-10 cm, 0 cm represented an absence
of sensation and 10 cm represented highest intensity of sensation). This was
done before and after therapy.
Blood pressure / Heart rate
During several visits before, during and after therapy, blood pressure (BP)
and heart rate (HR) were measured in a sitting position by standard
sphygmomanometry.
Statistical analysis
Total nasal symptom VAS score was the primary outcome variable. No for-
mal power calculation underlies this sample size.
Nasal symptom VAS data (10 repeated measurements under treatment) were
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analysed using repeated measures analysis of variance after log transforma-
tion with the baseline measurement as covariate.  Exponential time trends,
differences in time trends and, if no significant differences were found, con-
stant differences in mean level between the two treatment groups were tested
The various DRC symptom scores are defined in Table 2. DRC symptom
scores were aggregated in six periods by averaging the daily scores per pe-
riod per patient. The following six periods were distinguished: a baseline
period of 3 weeks (period 0), period 1 (week 4 and 5 after baseline), period
2 (week 7 and 8), period 3 (week 10), period 4 (week 17) and period 5 (week
41). These aggregated data were analysed using repeated measures analysis
of variance with the baseline average as covariate, the period as a within-
patient factor (with five levels) and treatment as a between-patient factor
with two levels. The interaction between period and treatment was also tested.
The residuals were assumed to have a Gaussian spatial covariance structure
accounting for differences in time between the repeated measurements.
UPSIT data were analysed using analysis of covariance with the baseline
measurement as covariate for between-group differences. Within-group
changes from baseline were tested using the paired t-test.
CDA data were analysed after log2 transformation using repeated  measures
analysis of variance with the baseline measurement as covariate. By this
transformation, effects are expressed in doubling dose units.
Mucosal sensibility VAS data and capsaicin sensitivity data were analysed
using nonparametric tests: the Wilcoxon signed rank test for within group
changes and the Mann-Whitney U-tests for differences between the two
groups. For capsaicin sensitivity the paired Wilcoxon test was applied after
log transformation.
Acoustic rhinometry, PNIF, heart rate, systolic and diastolic blood pressure
were analysed using repeated measures analysis of variance with the base-
line measurement as covariate. For acoustic rhinometry, the sum of right and
left for MMCA1 (TMMCA1) and MMCA2 (TMMCA2) was taken. Linear
time trends were tested, as well as differences in time trends between the
two treatment groups.
For differences in heart rate, and in systolic and diastolic blood pressure
between the two treatment groups, differences between the visits and the
interaction between these factors were tested. The null hypothesis is that the
63
mean outcome variable does not change in time and is the same for both
groups.
For all tests the significance level was set at 0.05. If appropriate,  95 %
confidence intervals (CI) of  between-groups differences in treatment effect
are presented.
RESULTS
The application of XylocaineR 10% spray in the nasal airway was immedi-
ately followed by a painful sensation that was described by all subjects as
most unpleasant.
Patients did not complain of irritation of nose and lips during or after capsai-
cin/placebo application. We feel this study was effectively blinded for both
patients and investigator.
Pre-treatment baseline data for patient characteristics and for efficacy
variables per group are shown in Table 3 for both groups.
Table 3. Baseline data
Group A Group B
Number of patients (male patients) 15 (6) 15 (8)
Age * (years) 33 (17 - 54) 37 (16 - 65)
VAS Overall nasal symptoms * 6.4 (2.5 - 9.5) 8.2 (2.8 - 9.7)
VAS Rhinorrhea * 4.3 (0.1 - 9.1) 5.2 (0.2 - 9.6)
VAS Obstruction * 6.7 (0.8 - 9.7) 7.2 (4.7 - 9.9)
VAS Sneezing * 1.8 (0.1 - 7.9) 3.5 (0.0 - 9.7)
VAS Epicritic sensibility * 2.5 (0.1 - 6.5) 4.6 (0.1 - 9.7)
VAS Protopathic sensibility * 1.9 (0.3 - 6.5) 4.1 (0.3 - 9.8)
TMMCA 1 # (cm2) 1.3 (0.30) 1.0 (0.19)
TMMCA 2 # (cm2) 1.3 (0.39) 1.0 (0.40)
PNIF # (l) 172 (66) 147 (71)
CDA threshold dose * (l) 50 (12.5 – 200) 25 (12.5 - 400)
Capsaicin sensitivity * (M) 1.0 10-6 (4.6 10-8 to 4.6 10-6) 1.0 10-6 (4.6 10-8 to 2.2 10-6)
# mean (standard deviation) * median (range)
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Symptoms
Visual analogue scale.   The improvement of the median for VAS ‘overall
nasal symptoms’ for both groups is shown in Fig. 2. In both groups a signifi-
cant improvement of overall nasal symptoms was observed (also described
later). Note the improvement started within 2 weeks after start of the treat-
ment with capsaicin (visit IV for group A and visit VIII / IX for group B).
In group A, the VAS score for ‘overall nasal symptoms’ decreased signifi-
cantly by 3.2 % per week after the start of treatment and in group B by 1.3 %,
the difference in time trend being significant (95 % CI: 0.4 - 3.5 % points; P
= 0.016). The VAS score for ‘rhinorrhea’ decreased significantly after the
start of treatment by 3.7 % per week in group A and by 2.6 % in group B, the
difference in time trend not being significant (P = 0.26). However, there was
a constant difference in VAS level: group B scored on average 2.1 times
higher than group A (95 % CI: 1.4 - 3.2; P = 0.0014).  The VAS score for
‘obstruction’ decreased significantly after the start of treatment by 3.2 % per
week in group A and by 1.8 % in group B, the difference in time trend being
significant (95 % CI: 0.01 - 2.9 % points; P = 0.0484). The VAS score for
‘sneezing’ decreased after the start of treatment by 2.8 % per week in group
A and by 1.3 % in group B, the difference in time trend not being significant
(95 % CI: -0.2 to 3.3 % points; P = 0.0916). Also no significant constant
difference in VAS level was seen between the two groups (95 % CI for group
B to A ratio: 0.8 - 3.6; P = 0.17). For all nasal symptoms, the within-group
VAS score decrease was significant in groups A and B (all P-values smaller
than 0.04).
Daily record chart.   For rhinorrhea, a significant mean difference was found
of 0.34 scale units ( 95 % CI: 0.01 - 0.67; P = 0.0424) in favour of group A.
A significant time effect was also found (P = 0.0002), showing a decrease in
DRC score from baseline. There was no evidence of a time by group interac-
tion (P = 0.76).
No significant difference between the groups was found for nasal blockage
(95 % CI: -0.38 to 0.30 scale units; P = 0.81). A significant time effect was
found (P = 0.0095), showing a decrease in DRC score from baseline. There
was no evidence of a time by group interaction (P = 0.24).
For all other DRC scores, no significant effects of time or treatment were
found.
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Smell
UPSIT.  The mean UPSIT score at visit 2 was 30 for group A (SD = 7.5) and
29 for group B (SD = 4.9). At visit 11, the mean score was 32 for group A (SD
= 4.6) and 29 for group B (SD = 7.6). No significant changes were found in
either group (P = 0.052 for group A and P = 0.67 for group B).  Also between
the two groups no significant difference (B – A) in level was found (95 % CI:
-6.2 to 0.3; P = 0.082).
Figure 2. Improvement in median VAS for ‘overall nasal symptoms’.
Patients in group A were first treated with capsaicin five times on a single day at intervals
of 1 h (visit 3). After 2 weeks, they received a total of five treatments with placebo once
every second or third day (visits 4-8). Patients of group B first received placebo five times
on a single day at intervals of 1 h (visit 3). This was followed two weeks later by a total of
five treatments with capsaicin once every second or third day (visits 4-8).
On every visit, they rated their ‘overall nasal symptoms’ on a visual analogue scale (0-
10cm). The change in median VAS score from visit 1 is shown.
In both groups a significant improvement of overall nasal symptoms was observed. Note
the improvement started within 2 weeks after start of the treatment with capsaicin (visit IV
for group A and visit VIII / IX for group B).
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CDA Hyperreactivity
Cold dry air provocation. The median of the threshold dose for cold dry air
provocation for both groups is shown in Fig. 3. In each group, there was a
significant change from baseline (visit 1) at post-treatment visits 10, 11 and
12 (all P-values smaller than 0.0001). There was no significant treatment by
visit interaction (P = 0.89). Also no significant constant difference in level
between the two groups (B – A) was found  (95 % CI: -1.6 to 0.3 doubling
dose units; P = 0.20).
Figure 3. Median threshold dose for cold dry air.
Patients in group A were first treated with capsaicin five times on a single day at intervals
of 1 h (visit 3). After 2 weeks they received a total of five treatments with placebo once
every second or third day (visits 4-8). Patients from group B first received placebo five
times on a single day at intervals of 1 h (visit 3). This was followed 2 weeks later by five
treatments with capsaicin once every second or third day (visits 4-8).
Nasal reactivity was measured using standardized cold dry air provocation before (visit 1)
and after (visit 10-12) therapy. The median threshold dose for cold dry air is shown.
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Nasal patency
Acoustic rhinometry.  The TMMCA1 increased significantly over time for
group A and almost significantly for group B: by 0.014 cm2 / week (P =
0.0027) for group A and by 0.009 cm2 / week (P = 0.0596) for group B. The
difference (B – A) in time trend was not significant (95 % CI: -0.018 to 0.007
cm2  / week; P = 0.42). Also no significant constant difference in level be-
tween the two groups (B – A) was found  (95 % CI: -0.06 to 0.07 cm2; P =
0.86).
The TMMCA2 had no significant linear time trend in either treatment group
(P = 0.78 for group A and P = 0.87 for group B). The difference in time trend
(B – A) was not significant (95 % CI: -0.018 to 0.017 cm2  / week; P = 0.94).
Also no significant constant difference in level between the two groups (B –
A) was found  (95 % CI: -0.05 to 0.13 cm2; P = 0.34).
Peak nasal inspiratory flow.  The time trend decreased by 0.12 l/s per week
in group A (P = 0.69) and increased by 0.30 l/s per week in group B (P =
0.30). The time trend in either treatment group was not significant, nor was
the difference (B – A) in time trend between the two treatment groups (95 %
CI: -0.39 to 1.21; P = 0.31). Also no significant constant difference in level
between the two groups (B – A) was found  (95 % CI: -65 to 3 l/s; P =
0.0732).
Sensitivity/sensibility nasal mucosa
Capsaicin sensitivity.  No significant differences were found (in either group)
between capsaicin sensitivity concentrations during and after therapy com-
pared with the capsaicin sensitivity concentration before therapy (P > 0.42).
In addition, no significant differences between the two groups were found
for all visits (P > 0.09).
Mucosal sensibility.  No significant changes from baseline were found in
either treatment group for either epicritic (P = 0.44 for group A and P = 0.055
for group B) and protopathic sensibility (P = 0.57 for group A and P = 0.064
for group B). No significant difference was found between the two therapy
groups (P = 0.51 for epicritic and P = 0.39 for protopathic sensibility).
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Safety
Blood pressure / Heart rate. For heart rate, systolic and diastolic blood
pressure, no significant effects of visit and group were found.
DISCUSSION
In a recent double blind placebo controlled study, we showed that repetitive
capsaicin administration for a total of seven applications in 14 days gives a
significant and long-term reduction of symptoms (15). The present study at-
tempted to find a capsaicin application regimen that was more practical for
both patient and doctor and at least equally effective as the previous one.
From our results, we can conclude that capsaicin treatment five times on a
single day at intervals of 1 h (group A) is at least as effective as capsaicin
treatment once every second or third day for a total of five treatments (group
B). Some study parameters like the VAS scores for ‘overall nasal symptoms’,
rhinorrhea and obstruction and the DRC score for rhinorrhea show even a
significant better treatment effect for capsaicin treatment on a single day
(group A).
A possible explanation for this is that, although the cumulative capsaicin
dose was the same for both treatment groups, the concentration of capsaicin
at the level of the nasal mucosa can reach much higher values for a longer
period in the group that is treated five times in 1 day than in the group treated
over a period of 5 days because of the wash-out effect in the latter group.
This seems to be in agreement with the hypothesis that capsaicin leads to a
selective degeneration/desensitization of peptidergic neurons in the nasal
mucosa because higher concentrations of capsaicin for one longer time pe-
riod can cause more degeneration/desensitization and reduce the opportuni-
ties for repair of these neurons than would be the case with five interrupted
shorter periods. More effective degenerating/desensitising could mean that
fewer neuropeptides will be released locally after irritating stimuli like cold
dry air (antidromic effect). Also  less sensory neural central stimulation might
take place after irritating stimuli giving less central protective neural reflex
mechanisms like secretion, extravasation and vasodilatation (orthodromic
effect).
This provides an attractive explanation for the significant therapeutic cap-
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saicin effect and the decrease in nasal hyperreactivity for cold dry air provo-
cation.
Patients repeatedly treated with intranasal capsaicin solution are found to
have reduced symptoms of pain and burning sensation with each successive
capsaicin application as a sign of capsaicin desensitization (21). We had
hoped to demonstrate, with our novel capsaicin sensitivity method, a de-
crease in capsaicin sensitivity after therapy as a result of the postulated cap-
saicin desensitization. However, this was not the case, perhaps because the
instrument is not sensitive enough and misses small alterations. It is also
possible that a learning effect in distinguishing between capsaicin and pla-
cebo masks a possible decrease in capsaicin sensibility. This latter phenom-
enon was observed in a group of normal individuals who were not treated
with capsaicin but only repeatedly tested for capsaicin sensitivity (unpub-
lished data).
Taking into account the results on the objective parameters of PNIF, acous-
tic rhinometry and CDA provocation in this study, it seems that the most
important underlying pathophysiology that results in symptoms in IR pa-
tients is increased hyperreactivity of the nasal mucosa rather than decreased
patency. This may also be an explanation for the correlation between the
decrease in nasal reactivity measured by CDA provocation and nasal com-
plaints, as well as for the absence of a significant change in PNIF and
TMMCA2. Furthermore, it seems that the values of PNIF and acoustic
rhinometry do not differ from values found in normal controls in other studies
(22, 23).
During the trial, we paid a lot of attention to safety data in order to identify
adverse side-effects. Because the concentration of capsaicin in the nasal
mucosa could reach higher values in group A, a different, possibly more
negative, effect on the safety data compared with group B was a possibility.
We therefore collected values for blood pressure, heart rate, olfactory func-
tion and mucosal sensibility and compared them before and after treatment
in and between the two groups. No significant differences were found so we
conclude that local capsaicin application seems safe in both treatment regi-
mens.
We conclude that local capsaicin nasal spray significantly reduces nasal
complaints in IR patients and that five treatments of capsaicin on a single
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day is at least as effective as five treatments of capsaicin in 2 weeks, and
even more effective in the reduction of nasal complaints measured with VAS.
We also conclude that intranasal capsaicin seems safe to use.
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Inflammatory cells seem not to be involved in idiopathic rhinitis.
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ABSTRACT
Mucosal inflammatory cellular infiltrates are correlated with nasal complaints
in symptomatic allergic rhinitis. Some authors suggest inflammation of a
neurogenic or immunogenic nature as an underlying disorder for idiopathic
rhinitis (IR). We looked at the possible involvement of inflammatory cells in
the pathogenesis of IR. Nasal biopsies were taken from sixty-five IR patients
with significant nasal complaints and from twenty healthy controls with no
nasal complaints. Inflammatory cells were quantified using monoclonal
antibodies directed against lymphocytes, antigen-presenting cells, eosinophils,
macrophages, monocytes, mast cells and other IgE-positive cells. No
significant differences were found, for any cell, between IR patients and
controls. We conclude that inflammatory cells do not seem to play an
important role in this meticulously characterised group of IR patients.
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INTRODUCTION
Idiopathic rhinitis (IR) is a diagnosis by exclusion. This disorder probably
represents a heterogeneous group of pathophysiological conditions. This
implies that the study group needs to be meticulously characterised. In a
group of non-atopic patients with nasal complaints, we excluded all patients
with systemic, allergic, medical and anatomical disorders that could explain
complaints of rhinorrhea, sneezing and/or nasal obstruction. This group with
unexplained nasal complaints was then homogenised on the basis of a daily
record chart on which patients had to reach a minimum symptom score. The
minimum was set using as a basis the definition of rhinitis put forward by
Mygind(Mygind and Weeke, 1985). In affected patients, periods of nasal
discharge, sneezing and congestion had to persist for an average of at least 1-
hour per day on at least five days during a period of fourteen days.
The proposed pathophysiological mechanisms for IR include a chronic in-
flammatory disorder of antigenic (local allergy) or neurogenic nature(Philip
and Togias, 1995, Carney and Jones, 1996, Shatkin et al., 1994). A pivotal
characteristic in the pathophysiological concept of inflammation is an influx
of inflammatory cells in the affected tissue. In symptomatic allergic rhinitis,
an increase of inflammatory cells has been observed in the nasal
mucosa(Bentley et al., 1992, Fokkens et al., 1990, Braunstahl et al., 2001).
We showed that cellular infiltrates (eosinophils, mast cells and IgE positive
cells) were not significantly different in a group of IR patients compared to
healthy controls (Blom et al., 1995). To ascertain the significance of inflam-
mation, we also need to know whether regulatory cells (lymphocytes and
antigen presenting cells) are involved in IR.
In this study, we examined nasal biopsies from 65 symptomatic IR patients
and 20 healthy controls without nasal complaints. The cell densities of CD1,
CD3, CD4, CD8, CD14, CD25, CD68, chymase, tryptase, IgE and BMK13
were studied in both layers of the nasal mucosa.
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MATERIALS AND METHODS
Subjects
Patients were studied in the outpatient ENT departments of the Leyenburg
Hospital in The Hague and the Erasmus Medical Centre Rotterdam Univer-
sity Hospital in Rotterdam, The Netherlands.
Patients were admitted to the study if they had a history of nasal complaints
such as nasal obstruction, sneezing, and rhinorrhea for a period of over 1
year which could not be attributed to allergic rhinitis, nasal or paranasal
sinus infection, anatomical disorders affecting nasal function, pregnancy or
lactation, systemic disorders and/or the use of medication affecting nasal
function (Table 1). Patients with nasal polyps were excluded, since they may
belong to a different pathophysiological group and their polyps may contrib-
ute to a higher symptom score for nasal blockage and/or rhinorrhea.
In affected patients, periods of nasal discharge, sneezing and congestion scored
using a daily record chart (DRC, table 2) had to persist for an average of at
least 1h per day on at least 5 days during a period of 14 days. Sixtyfive
patients participated under conditions of informed consent (male/female: 32/
33); the mean age was 34 years (range: 17-62). The ethnic origin of the patients
was: 56 Caucasian, 6 Asian, 2 Negroid and 1 Oriental. The control group
consisted of twenty healthy volunteers (male/female: 11/9); mean age 36 years
(range: 18-62), 16 Caucasian, 3 Oriental, and 1 Asian, without nasal complaints
or nasal abnormalities on ENT examination, a negative skin prick test for the
common inhalation allergens and a negative Phadiatop (Pharmacia, Uppsala,
Sweden). Patients and healthy controls were biopsied once. Procedures were
approved by the local Medical Ethics committees.
Nasal biopsies
At the time of the biopsy, all patients had nasal complaints, as confirmed by
their daily record charts. Controls did not suffer from nasal complaints. After
randomisation of the biopsy side, a biopsy of nasal mucosa was taken from
the lower edge of the inferior turbinate, about 2 cm posterior to the front
edge, using a Gerritsma forceps with a cup diameter of 2.5 mm (Fokkens et
al., 1988). Local anaesthesia was obtained by placing a cotton-wool carrier
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Inclusion criteria
- Age between 16 and 64 years.
- Negative skin prick test: house dust mite, tree pollen mix, grass pollen mix, mugwort, alternaria,
aspergillus, cladosporium, penicillum, dog, cat, parakeet, rabbit, hamster, horse, guinea pig.
(ALK-Diephuis, Holland)
- Negative Phadiatop (Pharmacia, Uppsala, Sweden)
- Symptoms for more than 1 year.
- Periods of nasal discharge, sneezing and congestion for an average of at least 1 h per day on at
least 5 days during a period of 14 days.
Exclusion criteria
- The use of systemic or inhaled corticosteroids within the previous month.
- Use of inhaled sodium cromoglycate or nedocromil sodium within the previous month.
- Use of astemizole within the previous month.
- Inability of the patient to stop taking medication affecting nasal function.
- A serious and/or unstable disease.
- Nasal surgery within the previous 6 weeks.
- Nasal polyps or a history of nasal polyps.
- Significant anatomical abnormalities affecting nasal function.
- Nasal or paranasal sinus infection (abnormal sinus X-ray).
- Pregnancy or lactation
- Abnormal findings at physical examination.
- Abnormal laboratory results for:
blood: Na, K, Ca, total protein, albumin, urea, creatinine, bilirubin, alkaline phosphatase, aspartate
aminotransferase, alanine aminotransferase, gammaglutamyl transpeptidase, haemoglobin, red
blood cell count, plasma cell volume, mean corpuscular volume, platelets, total white blood cell
count, neutrophils, lymphocytes, monocytes, eosinophils, basophils.
urine: blood, protein, glucose.
Table 1. Selection criteria for idiopathic rhinitis
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with 50 mg of cocaine and one drop of adrenaline (1:1000) under the inferior
turbinate without touching the biopsy site. The specimens were embedded
in Tissue-Tek II O.C.T. compound and frozen immediately.
Staining procedures
Monoclonal antibodies (mAb) directed against CD1, CD3, CD4, CD8, CD14,
CD25, CD 68, chymase, tryptase, IgE, and BMK13 (table 3) were used to-
gether with the supersensitive immunoalkaline phosphatase (ss-AP) method.
Six micron thick sections of nasal mucosa were cut on a cryostat (Jung Frigocut
2800E/20/40), transferred to poly-L-lysine-coated microscope slides, dried,
and fixed in acetone for 10 minutes at room temperature. They were then
Possible scores on the daily record chart
Nasal blockage:
(not being able to breathe freely through the nose)
Clear nasal discharge: (runny nose)
0 = absent
1 = between 0-1 h per half day
2 = between 1-2 h per half day
3 = more than 2 h per half day
Sneezing
Coughing
0 = absent
1 = less than 5 periods per half day
2 = between 5-10 periods per half day
3 = more than 10 periods per half day
Mucus production:
(yellow, green or brown)
0 = absent
1 = present
Table 2. Specimen of the daily record card for defining nasal symptoms in patients with
idiopathic rhinitis.
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rinsed in phosphate-buffered saline (PBS, pH 7.2), placed in a half-auto-
matic stainer (Sequenza, Shandon), incubated with 2 % bovine serum albu-
min in PBS for 10 minutes and incubated with normal goat serum (CLB,
Amsterdam, The Netherlands) for 10 minutes. The slides were then incubated
with the mAb for 30 minutes at room temperature.
The sections were then rinsed again in PBS for 5 minutes and incubated for
30 minutes with a biotinylated goat anti-mouse (1:50) immunoglobulin
antiserum, rinsed successively in PBS, incubated with strept Avidin AP (1:50)
(Biogenics, Klinipath, Duiven, Netherlands) for 30 minutes at room
temperature, rinsed in PBS and TRIS buffer (pH 8.0), and incubated for 30
minutes with a new fuchsin substrate (Chroma, Kongen, Germany). Finally,
the sections were rinsed with distilled water, counterstained with Gills
hematoxylin and mounted in glycerin-gelatin. Control staining was performed
Antibody Specificity Titer Source
CD1 OKT6 1:100 Dept. Immunology, Erasmus University, Rotterdam, The Netherlands
(NL)
CD3
CD4
CD8
CD25
leu4
leu3
leu2
IL2-r
1:25
1:50
1:100
1:150
BDH, Dorset, UK
B7
G3
Chymase
Tryptase
1:100
1:250
Chemicon, Temecula, Calif, USA
BMK13 M BP 1:200 Sanbio, Uden, NL
CD14
anti-IgE
mon/1
IgE
1:20
1:250
Central laboratory of the Netherlands Red Cross Blood Transfusion
service (CLB), Amsterdam, NL
CD68 KI-M 6 1:50 Behring, M arburg, Germany
Table 3. Monoclonal antibodies used to study muscosal biopsies in patients with idiopathic
rhinitis and controls.
80
by substitution with PBS and incubation with an irrelevant mAb of the same
subclass.
Light-microscopic evaluation
Stained cells were counted in two sections of each biopsy specimen. The
epithelium and lamina propria were evaluated separately. The total surface
area of the sections and their main parts (i.e. the epithelium and the lamina
propria) were estimated using the Kontron Image Analysis System Videoplan.
The number of cells/mm2 was calculated for the epithelium and the lamina
propria.
Statistical analysis.
The non-parametric Mann-Whitney test was used to compare the difference
in cell counts between the two groups. A p-value < 0.05 was considered to
indicate a significant difference. In order to have some idea of the magni-
tude of a Type II error in this study, the 97.5 upper confidence limit of the
mean difference between patients and controls was calculated after ln-trans-
formation of the cell counts. The ln-transformation compensates for the posi-
tive skewness so as to justify parametric inference more properly. The antilog
of this upper confidence limit divided by the antilog of this mean difference
gives the maximum ratio between the larger and the smaller median that
would still be accepted at the 5% level (2-sided), given the non-significantly
different observed medians in patients and controls. We call this ratio (which
by definition is larger than one) the smallest detectable ratio of medians
between the two groups for a particular variable in this study. The more lack
of power (i.e., the larger the Type II error), the higher this ratio will be. It is
assumed here that the distribution of the variable considered is lognormal so
that the geometric mean coincides with the median.
For instance, if the smaller of both medians for CD3 epithelium equals 512
in the control group and the calculated smallest detectable ratio of medians
between the two goups is 1.57, then the patient group would be significantly
different from the control group if the median is at least equal to 1.57 x 512
= 804.
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RESULTS
Biopsy specimen
The sections of the nasal mucosa had an average surface area of 1.6 mm2
and usually had a lining of ciliated columnar epithelium with or without
goblet cells and/ or partially stratified cuboidal epithelium. The lamina propria
usually consisted of a looser subepithelial cell-rich layer with most of the
mucous glands and a deeper collagenous cell-poor layer. All sections were
sufficiently deep to assess both layers. The sections were generally of good
quality. It was not possible to evaluate two biopsy specimens. One exclusion
was made because of an artefact resulting from defrosting of the specimen
and the other specimen was displaced. The mAb-ss-AP staining showed red
cells against a blue counterstained background. Biopsy specimens from 2 of
the 65 patients showed substantial numbers of eosinophils, mast cells and
IgE-positive cells.
T-lymphocytes
These small round cells were abundantly present in the epithelium and in the
lamina propria. Sometimes, clusters of T-cells (500-1000 cells) were found
in the lamina propria. There was no difference between the groups in terms
of the presence of these clusters.
The numbers of CD3, CD4, CD8, and CD25 positive cells/mm2 are shown in
table 4. As can be seen, hardly any IL-2 receptor (CD25) positive cells were
found in either layer of the nasal mucosa. If there were any differences
between the two groups at all, they were not statistically significant.  The
smallest detectable ratios of medians between the groups were, respectively:
CD3 epithelium (EP) 1.57, CD3 lamina propria (LP) 1.47, CD4 EP 1.78,
CD4 LP 1.5, CD8 EP 1.88, CD8 LP 1.73, CD25 EP 2.63, CD25 LP 2.38.
Langerhans cells
This large dendritic cell was found mostly in the epithelium. Only a few
were present in the lamina propria. The numbers of CD1-positive cells are
shown in table 4. No significant differences were found. The smallest
detectable ratios of medians between the groups were, respectively: CD1 EP
1.86, CD1 LP 2.20.
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Table 4. Median (25th and 75th percentile of positive cells/mm2 in epithelium and lamina
propria of the nasal mucosa.
  Cell type Controls Patients p-value
Median (25 %-75%) Median (25%-75%)
Epithelium
CD1 48 (15-130) 54 (15-110) 0.82
CD3 512 (299-867) 630 (347-1079) 0.27
CD4 545 (341-755) 424 (223-584) 0.18
CD8 305 (173-431) 446 (163-762) 0.11
CD14 310 (130-497) 215 (179-316) 0.68
CD25 8 (0-30) 0 (0-25) 0.43
BMK13 0 (0-0) 0 (0-0) 0.60
Tryptase 0 (0-4) 0 (0-4) 0.88
Chymase 0 (0-0) 0 (0-8) 0.06
IgE 0 (0-0) 0 (0-28) 0.30
CD68 165 (89-293) 214 (136-378) 0.06
Lamina propria
CD1 3 (1-8) 5 (1-13) 0.54
CD3 678 (486-832) 552 (300-872) 0.31
CD4 464 (181-885) 426 (259-611) 0.65
CD8 269 (160-345) 295 (147-476) 0.51
CD14 232 (143-367) 196 (161-271) 0.58
CD25 7 (2-58) 3 (0-13) 0.30
BMK13 0 (0-0) 0 (0-3) 0.18
Tryptase 65 (41-71) 69 (38-97) 0.30
Chymase 54 (47-71) 63 (46-100) 0.35
IgE 8 (2-62) 22 (4-64) 0.67
CD68 145 (74-195) 152 (101-250) 0.30
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Macrophages and monocytes
The CD68 positive cells were large cells with a bright staining cytoplasm.
These cells were found to be equally distributed in both layers, as was CD14.
The numbers of CD68 and CD14 cells are shown in table 4. No significant
differences were found. The smallest detectable ratios of medians between
the groups were, respectively: CD14 EP 1.68, CD14 LP 1.55, CD68 EP 1.44,
CD 68 LP 1.52.
Mast cells and other IgE-positive cells
The chymase and tryptase and IgE-positive cells were found mainly in the
lamina propria. The numbers are shown in table 4. No significant differences
were found. The smallest detectable ratios of medians between the groups
were, respectively: anti-IgE EP 4.22, anti-IgE LP 3.17, tryptase EP 2.62,
tryptase LP 1.57, chymase EP 2.47, chymase LP 1.61.
Eosinophils
The numbers of BMK13 positive cells found in the nasal mucosa of both
patients and controls were negligible. The numbers are shown in table 4. No
significant differences were found. The smallest detectable ratios of medians
between the groups were, respectively: BMK13 EP 1.96, BMK13 LP 2.21.
DISCUSSION
Wolf suggested that IR could be the result of an “over-active” non-adrener-
gic non-cholinergic system(Wolf, 1988). Stimulation of sensory neurons re-
sults in rhinorrhea, nasal blockage and sneezing(Baraniuk, 1992). Sensory
neural stimulation may produce these effects either through a central neural
reflex, associated with efferent parasympathetic neurotransmission, or via
anti-dromic release of neuropeptides from sensory neurons (Lundblad et al.,
1983). This hypothesis was corroborated by the findings of Lacroix, who
reported an increased concentration of neuropeptides in a group of chronic
nonallergic rhinitis patients (Lacroix et al., 1992), improvement of symptoms
by local treatment of capsaicin giving a 50% reduction in CGRP-like immu-
noreactivity(-LI) content in nasal biopsies (Lacroix et al., 1991), and a corre-
84
lation between symptom intensity and CGRP-LI concentration in nasal mu-
cosa (Lacroix et al., 1995).
An increase of proinflammatory neuropeptides may result in a stimulation of
T-cell proliferation, stimulation of mast cells, macrophages and eosinophils,
and chemoattraction of eosinophils and neutrophils(Joos et al., 1995). Sub-
stance P can increase the percentage of neutrophils recovered from nasal
lavage (Braunstein et al., 1994). Capsaicin, a specific activator of sensory
nerve endings, induces a neurogenic inflammation, with an influx of inflam-
matory cells in nasal lavage after a single provocation (Philip et al., 1996).
Another theory concerning the pathogenesis of IR is that of a local, occult
allergy (Carney et al., 2001, Powe et al., 2001, Shatkin et al., 1994). The
diagnosis of IR is made by exclusion. An allergy test is not 100% sensitive
and systemic manifestations of atopic disease, such as a positive skin prick
test or RAST, may be missed because the nose is a small shock organ. In
seasonal or perennial allergic rhinitis, increased numbers of inflammatory
cells, such as Langerhans cells, IgE positive cells and eosinophils, can be
found in the nasal mucosa as a sign of inflammation (Bentley et al., 1992,
Fokkens et al., 1990, Braunstahl et al., 2001).
By strict selection and by using a complaint threshold value, we tried to
achieve a homogenous group of patients. The 2 patients of the total of 65
patients with negative allergy tests who had a substantial typical cellular
allergic infiltrate in the nasal mucosa were classified as possible sufferers
from an occult local allergy and or non-allergic rhinitis with eosinophil syn-
drome (NARES) (Mikaelian, 1989). This would mean a maximum preva-
lence of three percent of occult allergy/NARES in this group that can be
discerned by nasal biopsies. No other signs of inflammation were found in
this IR patient group.
This contrasts with a recent study of Powe et al. who found significantly
more nasal mucosa mast cells and eosinophils in a group of IR (and allergic
rhinitis) patients compared to a group of normal individuals(Powe et al.,
2001). They examined whole, full-length, full-thickness concha inferior speci-
mens resected under general anaesthesia.
The difference in study outcome may be explained by a more severe pathol-
ogy in the IR group of Powe et al. warranting total turbinectomy. Another
explanation could be the difference in biopsy size (average surface area of
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1.6 mm2 in our study). Nasal cellular infiltrates show a focal localisation of
cell populations which can be better averaged in larger biopsies.
It may also be the case that our IR patient group contains significantly fewer
NARES patients (2 of the 65) compared to the patient group studied by Powe
et al. The reason for this could be the fact that a Dutch rhinitis patient will
not be sent to the ENT department before being treated with local
corticosteriods by his or her general practitioner (Lundblad et al., 2001). In
addition, as might be expected, it seems that NARES patients and or patients
with an occult local allergy form an IR subgroup which responds well to
nasal corticosteroids (Small et al., 1982).
The data presented concurs with the data from Sanico, who was unable to
find an increased responsiveness to capsaicin in a group of 8 non-allergic
rhinitis patients. He therefore argued against a central role for capsaicin sen-
sitive nerves (pivotal in the concept of neurogenic inflammation) in the patho-
physiology of IR (Sanico et al., 1998).
The question then arises as to whether this immunohistochemical evaluation
method is sensitive enough to detect significant differences between the groups.
The calculated ratios between the geometric means of both groups indicating
threshold significance at the 5% level are within the range found in patients
with chronic allergic rhinitis (Godthelp et al., 1996, Fokkens et al., 1990). In
these studies, which compare symptomatic allergic patients to asymptomatic
controls, cellular differences between patients and controls were indeed found,
while the distribution of the number of immunocompetent cells/mm2 was in
the same order of magnitude as in this IR study. We therefore think it is justi-
fied to assume that if significant mucosal inflammation was present, we would
have detected it. The lack of differences in cell numbers does not exclude a
functional cellular involvement. However, in two other studies, we failed to
ascertain a relation between the number of immunocompetent cells and nasal
complaints in IR patients (Blom et al., 1998, Blom et al., 1997a). A signifi-
cant reduction of immunocompetent cells in the nasal mucosa of IR patients
treated with nasal steroids (fluticasone aqueous nasal spray) was not accom-
panied by a reduction in nasal complaints (Blom et al., 1997a) and, inversely,
a significant reduction in nasal complaints in a group of IR patients treated
with topical capsaicin aqueous nasal spray was not accompanied by a change
in inflammatory mediators (Blom et al., 1997b) or a reduction in the numbers
of inflammatory cells (Blom et al., 1998).
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Given the above, we conclude that inflammatory cells do not seem to play an
important role in this meticulously characterised group of IR patients.
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CHAPTER VI
The Long-term Effects of Capsaicin Aqueous Spray on the Nasal Mucosa.
H. M. Blom,  L. A. W. F. M. Severijnen,  J. B. van Rijswijk,
P. G. H. Mulder, R. Gerth van Wijk and W. J. Fokkens.
Clinical and Experimental Allergy, 1998, volume 28: pp 1351-1358
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ABSTRACT
Background: Capsaicin has been shown previously to reduce nasal com-
plaints in patients with idiopathic rhinitis. Proposed pathophysiological
mechanisms for idiopathic rhinitis include a chronic inflammatory disorder
of an antigenic or neurogenic nature as well as the possibility of a functional
neuronal disorder. We hypothesized that the beneficial effect of capsaicin
might be the result of a down-regulation of inflammation (by a reduction of
inflammatory cells) or through modulation of neural tissue density.
Methods: Patients were treated with either a placebo or capsaicin spray so-
lution delivering 0.15 mg of capsaicin per nostril once every second or third
day for a total of seven treatments. Both sides were treated each visit. Biop-
sies were taken before and 2 weeks, 3 months and 9 months after the treat-
ment period. Immunohistochemical staining of the biopsy specimen was
performed to ascertain the effect of treatment on immunocompetent cell
densities (quantitative) and neural tissue densities (semi-quantitative) in the
nasal mucosa.
Results: Nasal complaints were significantly reduced in the capsaicin-treated
group. The number of CD1+, CD25+, CD3+, CD68+, BMK13+, IgE+,
tryptase+, and chymase+ cells did not significantly differ between capsaicin
and placebo group. No significant differences between both groups were
found in pan-neurogenic staining of nasal mucosa using neurofilament and
synaptophysine.
Conclusion: Capsaicin aqueous nasal spray has previously been shown to
reduce nasal complaints without affecting cellular homeostasis or overall
neurogenic staining up to 9 months after treatment. Immunocompetent cells
are not involved in idiopathic rhinitis.
INTRODUCTION
In a double-blind placebo-controlled study we recently demonstrated that
capsaicin is highly effective in controlling idiopathic rhinitis (1). A long-
lasting relief in symptoms was obtained for at least 9 months.
Capsaicin is the pungent agent in red peppers. Its mode of action is well
documented in rodents, where it affects mainly the thin, unmyelinated sen-
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sory nerve fibres. It causes initial stimulation (with release of endogenous
neuropeptides), followed by desensitization to capsaicin and other sensory
stimuli (2). With higher doses, long-term functional or even morphological
ablation of the thin sensory neurons occurs (3). In humans, the effect of
capsaicin has not been fully documented (4). Moreover, the pathophysiologi-
cal mechanism for idiopathic rhinitis is not understood. Proposed mecha-
nisms include a chronic inflammatory disorder of an antigenic or neuro-
genic nature, or a functional neuronal disorder (5,6).
To study whether capsaicin reduces inflammation or modulates nasal neuronal
tissue densities we performed a nasal biopsy study in 24 patients with
idiopathic rhinitis. Cells were quantified per square millimetre and the
sections stained with neuronal markers were scored semi-quantitatively for
morphometric changes.
MATERIALS AND METHODS
Subjects
Patients were admitted to the study if they had a history of nasal complaints
such as nasal obstruction, sneezing, and rhinorrhea for a period of over 1
year which could not be attributed to allergic rhinitis, nasal or paranasal
sinus infection, anatomical disorders affecting nasal function, pregnancy or
lactation and/or systemic disorders (7,8). They were non-smokers not using
medication affecting nasal function. Patients with nasal polyps were excluded,
since they may belong to a different pathophysiological group and their polyps
may contribute to a higher symptom score for nasal blockage and/or
rhinorrhea.
Study design
Thirty-five patients with the diagnosis of idiopathic rhinitis scored nasal block-
age, clear discharge, sneezing and coughing using a four point scale; mucus
production (absent or present) was noted for a period of 2 weeks using a
daily record card (1,7,8). Mucus production or coughing were used as indi-
cators of upper airway infection. If present they led to exclusion of the pa-
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tient. Patients were included in this study if periods of clear nasal discharge,
sneezing and nasal blockage persisted for an average of at least 1 h/day for at
least 5 days during a period of 14 days. The duration of complaints during
the day was used as the prime criterion for further study. Twenty-five of the
35 patients were found eligible for our study and participated under condi-
tions of informed consent (male/female: 16/9); mean age was 36 years (range:
18-60 years). One of the 14 capsaicin patients could not continue after three
capsaicin applications because of influenza with fever.
Procedures were approved by the local medical ethics committee.
Patients were randomized in a double-blind placebo-controlled fashion and
treated with placebo (11 persons) or capsaicin (14 persons). A total of seven
treatments over a period of 2 weeks were given.
Treatment procedure
The nose was decongested with xylometazolinehydrochloride 0.1% and anaes-
thetized with lidocaine base-spray (100 mg/mL). Capsaicin aqueous nasal
spray (0.15 mg) or placebo were instilled in each nostril (1). The application
of Xylocaine spray in the nasal airway was immediately followed by a
painful sensation that was described by all subjects as most unpleasant. Pa-
tients did not complain of irritation of nose and lips during or after capsaicin/
placebo application. At every visit the subjects rated nasal symptoms on a
visual analogue scale (0-10 cm; 0 represented absence of symptoms and 10
represented high intensity of symptoms). Daily record card scoring was con-
tinued for up to 2 weeks after treatment (1).
Nasal biopsies were taken four times: at the run-in period, and 2 weeks, 3
months and 9 months after the treatment period (Fig. 1). After randomization
of the biopsy side, specimens of nasal mucosa were taken from the lower
edge of the inferior turbinate, about 2 cm posterior to the front edge, using a
Gerritsma forceps with a cup diameter of 2.5 mm (9). Local anaesthesia was
obtained by placing a cotton-wool carrier with 50 mg of cocaine and one
drop of adrenaline (1:1000) under the inferior turbinate without touching the
biopsy site. The specimens were embedded in Tissue-Tek II OCT (Sakura
Finetek Europe BV, Zoeterwoude, The Netherlands) compound and frozen
immediately.
Blood: (sodium, potassium, calcium, total protein, albumin, urea, creatinine,
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bilirubin, alkaline phosphatase, aspartate aminotransferase, alanine
aminotransferase, gammaglutamyl transpeptidase, haemoglobin, red blood
cell count, plasma cell volume, mean corpuscular volume, platelets, total
white blood cell count, neutrophils, lymphocytes, monocytes, eosinophils,
basophils) and urine: (blood, protein, glucose) samples were taken during
visits one and nine to monitor changes during therapy.
Staining procedures
Monoclonal antibodies (mAb) directed against synaptophysine, neurofilament,
CD1, CD3, CD25, CD68, IgE, MBP, chymase and tryptase (Table 1) were
used together with the super sensitive immunoalkaline phoshatase (ss-APAAP)
method. Sections of nasal mucosa were cut at 6 µm on a cryostat (Jung Frigocut
2800E/20/40), transferred to poly L-lysine-coated microscope slides, dried
Fig. 1. Study design during the entire study period patients scored their nasal
complaints such as nasal blockage, clear discharge, sneezing, coughing and mucus
production on a daily record card. After the first 2 weeks (0-2, run-in) patients with
periods of nasal blockage, clear nasal discharge, and sneezing persisted for an average of
at least 1 h/day for at least 5 days during the 14 day period. Mucus production and
coughing were used as upper airway indicators. If present they led to exclusion of the
patient. A biopsy was taken in included patients. Weeks 2-4 were used to allow healing of
the nasal mucosa before treatment. During weeks 4-6 a total of seven treatments were
given. During the evaluation period (weeks 6-42) three nasal biopsies were taken.
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and fixed in acetone for 10 min at room temperature. They were next rinsed in
phosphate-buffered saline (PBS, pH 7.2), placed in a half-automatic stainer
(Sequenza, Shandon, Amsterdam, The Netherlands) and incubated with normal
goat serum (CLB, Amsterdam, The Netherlands) for 10 min. Following this
the slides were incubated with the mAb for 60 min at room temperature. The
sections were then rinsed again in PBS for 10 min and incubated for 30 min
with a goat antimouse (1:50) biotin, rinsed successively in PBS, incubated
with streptavidin alkaline phophatase supersensitive (1:50) (Biogenex,
Klinipath, Duiven, The Netherlands) for 30 min at room temperature, rinsed
in PBS and TRIS buffer (pH 8.5), and incubated for 30 min with a new
fuchsin substrate (Chroma, Kongen, Germany). Finally, sections were rinsed
with distilled water, counter-stained with Gill’s haematoxylin and mounted
in glycerine-gelatine. Control staining was performed by substitution with
PBS and incubation with an irrelevant mAb of the same subclass.
Light-microscopic evaluation
Stained cells were quantified (‘blinded’) in two sections of each biopsy
specimen. The epithelium and lamina propria were evaluated separately. The
total surface area of a section and its main parts (i.e. the epithelium and the
lamina propria) were estimated with the use of the Kontron Image Analysis
System Videoplan (Zeiss, Weesp, The Netherlands). The number of cells/
Table 1. Monoclonal antibodies used to study nasal biopsy specimen
Antibody Specificity Titre Source
OKT6 CD1 1 : 100 Dept. Immunology, Erasmus University, Rotterdam
leu4 CD3 1 : 25 BDH, Dorset. UK
KIM-6 CD68 1 : 100 Behring, Rijswijk, NL
2F11 Neurofilament 1 : 50 Sanbio, Uden, The Netherlands
Sy38 Synaptophysine 1 : 20 Dakopatts, ITK, Uithoorn, NL
IgE 1 : 250  Central laboratory of the Netherlands Red Cross Blood 
Tranfusion service (CLB), Amsterdam, NL
IL-2r CD25 1 : 150 BDH, Dorset. UK
BMK13 MBP 1 : 200 Sanbio, Uden, The Netherlands
B7 Chymase 1 : 100 Chemicon, Temecula, Calif. USA
G3 Tryptase 1 : 250 Chemicon, Temecula, Calif. USA
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mm2 was calculated for the epithelium and the lamina propria. The intensity,
number and dimensions (width and length) of neuronal staining was semi-
quantified by three separate observers. Biopsies were ranked 1-24 by
continuously comparing the biopsies amongst another until all were ranked,
by each separate observer. In practice a section would be taken at random,
evaluated and put down. The next section would be taken at random and
graded for stronger or weaker staining compared with the previous section.
The next section would be stronger, weaker, or in between the two previous
sections. At the end all sections would be ‘on the table’ and the weakest
stained section would receive rank 1 and the strongest stained section would
receive rank 24.
Statistical analysis
The non-parametric Mann-Whitney U-test was used to compare the differences
in cell counts between the groups. A P-value < 0.05 was considered to indicate
a significant difference. The Spearman rank correlations between changes in
cell numbers and the changes in the visual analogue scale scores per
randomization group were calculated. For the interobserver variation, the
rank correlation between the rankings of any two observers was calculated
per visit for synaptophysine and neurofilament. Differences in ranking between
any two observers were also calculated. The mean rank averaged over the
three observers was used to compare the two treatment groups per visit,
using the Mann-Whitney U-test.
RESULTS
Biopsies
General description
The sections of the nasal mucosa had an average surface area of 2.0 mm2 and
usually showed a lining of ciliated columnar epithelium with or without goblet
cells and/or partially stratified cuboidal epithelium. The lamina propria
consisted usually of a looser subepithelial cell-rich layer with mucous glands
and a deeper collagenous cell-poor layer. All sections were sufficiently deep
to assess both layers. The sections were generally of good quality. No structural
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damage to the mucosa was seen after capsaicin treatment (thickness of the
epithelium, thickness of basal membrane, number and size of glands).
Inflammatory cells
The results are shown in Tables 2a and 2b. The mAb-ss staining showed red
cells against a blue counter-stained background. T lymphocytes, small round
cells, were abundantly present in the epithelium as well as the lamina propria
(Fig. 2). Sometimes clusters of T cells were found in the epithelium or lamina
propria (500-1000). The occurrence of these clusters did not differ between
the groups. Langerhans cells, large dendritic cells, were found mostly in the
Table 2. Median cell numbers and 25th and 75th percentiles for capsaicin and placebo
treatment at the end of the run-in period and 2 weeks, 18 weeks and 42 weeks after treat-
ment. (a) In the epithelium; (b) In the lamina propria
Table 2a.
Epithelium
Treatment plac caps Plac caps Plac caps Plac caps
CD1 379 341 451 447 275 355 230 350
25% 346 159 221 269 211 261 93 100
75% 846 425 970 791 591 529 278 621
CD3 1457 624 943 821 732 1340 1244 1339
25% 561 438 378 677 572 737 762 301
75% 2105 1432 1049 1557 1013 2992 1955 2667
CD25 84 34 59 86 52 50 44 36
25% 53 15 29 32 16 30 18 19
75% 128 92 67 176 182 195 64 129
CD68 455 578 512 587 480 1037 595 487
25% 228 340 334 379 305 472 421 377
75% 1934 800 709 856 1440 2071 875 1842
BMK 13 8 3 25 9 9 7 13 3
25% 1 2 0 2 0 0 0 0
75% 65 22 29 110 67 152 56 37
Tryptase 11 6 11 25 18 27 15 13
25% 0 4 0 0 0 11 0 0
75% 26 17 56 115 109 100 51 45
Chymase 0 3 16 12 7 15 14 36
25% 0 0 0 0 0 2 3 0
75% 8 56 26 61 18 42 19 105
IgE 74 123 57 36 153 56 29 20
25% 9 6 0 3 7 2 0 0
75% 311 206 420 160 182 269 344 185
Run in 2 weeks 18 weeks 42 weeks
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epithelium. Only a few were present in the lamina propria. Mast cells were
found mostly in the lamina propria and hardly ever in the epithelium (Fig. 3).
Eosinophils were hardly ever present in our material. Sometimes moderate
infiltrates were found in the mucosa. The occurrence did not differ between
the groups. The CD68 positive cells were large cells with a bright staining
cytoplasm. This cell type was found to be equally distributed in both layers.
No significant changes were found between treatment and placebo for any of
the cells.
Table 2b.
Epithelium
Treatment plac caps Plac caps Plac caps Plac caps
CD1 58 31 27 52 48 35 9 18
25% 51 15 18 16 21 17 9 18
75% 67 6 54 79 70 95 46 90
CD3 1372 591 616 1151 964 1262 856 1386
25% 1055 407 366 576 759 632 433 639
75% 3191 1237 1125 1457 1451 2172 2139 2552
CD25 50 36 47 82 24 43 28 45
25% 30 20 23 41 17 8 13 11
75% 93 75 79 141 51 97 54 83
CD68 384 312 267 477 320 573 380 544
25% 200 257 161 393 278 274 244 300
75% 911 675 752 571 831 984 524 965
BMK 13 23 11 16 51 18 15 16 39
25% 6 8 5 21 2 6 13 8
75% 45 43 53 89 52 77 38 93
Tryptase 199 192 194 302 212 205 171 248
25% 98 60 94 177 94 113 121 169
75% 281 402 494 448 387 395 213 479
Chymase 158 164 146 282 178 285 148 285
25% 100 93 62 112 123 119 98 189
75% 270 377 334 479 410 343 273 427
IgE 102 47 112 140 131 117 85 150
25% 55 30 45 75 34 36 35 55
75% 281 265 234 160 390 253 180 316
Run in 2 weeks 18 weeks 42 weeks
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Neuronal staining
Synaptophysine and neurofilament staining showed red fibres cut at different
angles (Figs 4 and 5). The rank correlation between any two observers varied
from r = 0.8 to r = 0.96. The differences in ranking between any two observers
varied between -8 and 11, with a mean and a median almost equal to zero, as
expected. No significant differences between the two treatment groups were
found for either synaptophysine or neurofilament staining.
Blood and urine
No significant changes were found for any of the blood or urine parameters.
DISCUSSION
The effect of capsaicin on nasal complaints and cellular mediators has al-
ready been described (1). To summarize, a 9 month amelioration of nasal
complaints was seen without an effect on cellular mediators.
The mode of action of capsaicin is not clear, neither is the aetiology of idi-
opathic rhinitis. Proposed mechanisms for idiopathic rhinitis include the pos-
Fig. 2. Lymphocytes in the nasal mucosa (CD3+). The epithelium, basal membrane and
lamina propria can be distinguished. Positive cells stain red. Lymphocytes are abundantly
present in both layers.
Fig. 3. Mast cells in the nasal mucosa (tryptase+). The different mucosal layers can be
distinguished. Mast cells are not present in the epithelium, but are abundantly present in
the lamina propria.
Fig. 4. Synaptophysine in the nasal mucosa. (a) Strong staining. Axial, transversal and
longitidinal cut fibres can be distinguished. No signal is seen in the epithelium. (b) Weak
staining. Mostly axial cut fibres are seen. One axial cut fibre is seen in the epithelium.
Fig. 5. Neurofilament in the nasal mucosa. (a) Strong staining. Mostly longitudinal cut
fibres are seen in both the epithelium and lamina propria. (b) Weak staining. Some longi-
tudinal cut fibres can be distinguished.
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sibility of a chronic inflammatory disorder. The beneficial effect of capsaicin
treatment could be the result of down-regulation of the inflammation, result-
ing in a reduction in the number of inflammatory cells. Knowledge on the
effect of capsaicin provocation on nasal cellular homeostasis is limited to
lavage studies following a single capsaicin dose. Philip et al. (10) described
biphasic inflammatory-cell influx with neutrophils, eosinophils and mononu-
clear cells (in nasal lavage) up to 4 h following capsaicin provocation. Roche
et al. (4) described an increase in neutrophils but not in other cells 10 min
after capsaicin challenge. Whether or not this reflects a ‘wash out’ by in-
creased nasal secretion, or an increase in mucociliary activity which could
sweep cells out of the sinuses, or a transmigration of immunocompetent cells
from the vessels through the nasal mucosa in the nasal lumen remains open for
discussion (10). Our nasal biopsy study circumvents the ‘wash out problem’
since it allows study of all mucosal layers. In a pilot study with three patients
(unpublished data) it was learnt that 2 weeks after the last capsaicin treatment
a new steady state in nasal symptomatology was reached. If a correlation was
to be found between the number of immunocompetent cells and nasal symp-
tomatology, this would be the moment to ascertain it, it was hypothesized.
The opportunity to study the direct effect of capsaicin on nasal immunocom-
petent cells (‘provocation effect’) was effectively missed since 2 weeks after
cessation of the neurogenic stimulus the supposed capsaicin-induced neuro-
genic inflammation may have withered and would therefore not be detected.
A biopsy taken directly after the first treatment was not considered opportun-
istic because six more treatments would follow.
No correlation was found between nasal symptomatology and any of the
immunocompetent cells, for any of the biopsies. Nor were any significant
cellular differences found between the placebo and the treatment group at
any of the biopsy time points. This could mean that: (1) cells are not an
integral part of the neurogenic response; or (2) the animal concept of neuro-
genic inflammation is not valid for the nasal airway, not even in inflamed
airways when a neural hyperresponsiveness has developed (11).
The absence of correlation between cells and symptoms (which is congruent
with our previous study in which a reduction in nasal immunocompetent cell
numbers was found in a group of idiopathic rhinitic patients treated with
fluticasone aqueous nasal spray without a reduction in nasal symptomatol-
101
ogy) (8), the absence of significant differences in the number of immunocom-
petent cells between capsaicin and placebo group, and the absence of an
increase in cellular mediators (as a sign of cellular activation) following
capsaicin challenge (1,12) raises the question of the relevance of the increase
of immunocompetent cells in nasal lavage after capsaicin challenge.
Again it is concluded that immunocompetent cells are not involved in idi-
opathic rhinitis (7,8).
Reports on the effect of capsaicin treatment on neuronal tissue are not con-
sistent. Lacroix et al. (13) showed a 50% decrease in CGRP-like immunore-
activity after capsaicin treatment of 16 patients with a drug-induced rhinitis
suggesting depletion or atrophy of the unmyelinated sensory nerve fibres. In
contrast, Wolf et al. (14), in a study of 123 patients, failed to show any reduc-
tion of peptidergic neurons within the nasal mucosa of 16 selected
(uncharacterized) patients. He suggested a blockage of receptors as the mode
of action. To quantify neuronal staining is difficult and often open to discus-
sion, as nerve fibres may have a different diameter and can be cut at differ-
ent angles, resulting in an abundant variation in staining morphology (Figs 4
and 5). A continuous ranking system was used. A very high Kappa for
interobserver variability was found, suggesting a reliable quantification
method. No significant differences were found between placebo and treat-
ment groups for neurofilament or synaptophysine staining. These antibodies
are pan-neurogenic markers. They do not allow discrimination between the
adrenergic, the cholinergic and/or the peptidergic system. The data suggests
that capsaicin does not induce gross changes in nervous tissue in the nasal
mucosa in idiopathic rhinitis patients. Other signs of capsaicin-induced mu-
cosal damage were not seen, and inflammatory cell densities were not af-
fected. Possible changes in the peptidergic system (the supposed site of ac-
tion of capsaicin) might not have been detected with these pan-neurogenic
markers.
Capsaicin aqueous nasal spray does significantly improve nasal
symptomatology in idiopathic rhinitic patients, without affecting cellular
homeostasis or overall neurogenic staining up to 9 months after treatment.
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CHAPTER VII
The direct effect of capsaicin aqueous spray on the nasal mucosa of
idiopathic rhinitis patients: a double-blind placebo controlled biopsy study.
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ABSTRACT
Background: To our knowledge, until now, data concerning the provocation
effect of capsaicin on nasal cellular homeostasis in humans is limited to
lavage studies following a single capsaicin application in allergic patients
and healthy controls.
Objective: To get more insight in the pathophysiologic mechanism of idi-
opathic rhinitis and the direct mode of action of capsaicin on nasal mucosa
cell counts and neurogenic staining.
Methods: We performed a double-blind placebo controlled nasal biopsy study
in 30 strictly selected and well-defined idiopathic rhinitis (IR) patients chal-
lenged with either capsaicin or placebo. Biopsies were taken at baseline 2
weeks before provocation and  15 minutes and 1 hour after a single provoca-
tion with capsaicin or placebo. The cell densities of CD3, CD8, CD25, C-
Kit, chymase, tryptase, BB1, IgE and BMK 13 and the neuronal staining
with synaptophysine, neurofilament, VRL-1 were studied in both layers of
the nasal mucosa.
Results: No significant difference in nasal mucosa cell counts and neuro-
genic staining were found 15 minutes and 1 hour after provocation. Only for
CD3 in the epithelium 1 hour after provocation a significant higher cell count
was found in the capsaicin group using the Mann-Whitney U test. Due to
multiple testing this p-value of 0.011 for CD3 could have been easily caused
by chance.
Conclusions: We conclude that capsaicin, after local anaesthesia of the nasal
mucosa, does not affect cellular homeostasis or neurogenic staining 15
minutes and 1 hour after nasal provocation in this double-blind placebo
controlled biopsy study. This strengthens us in our idea that inflammatory
cells do not play a role in the mode of action of capsaicin and the aetiology
of IR.
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INTRODUCTION
Syndromes of chronic rhinitis with an unknown aetiology include nonallergic
noninfectious perennial rhinitis, formerly referred to by us as NANIPER. In
accordance with the ‘’World Health Organisation Initiative, Allergic Rhini-
tis and its Impact on Asthma’’(1), we are using the term idiopathic rhinitis
(IR) to describe this pathology from now on. IR, formerly also called vaso-
motor rhinitis, is a diagnosis of exclusion and is given to patients who suffer
from perennial nasal congestion, rhinorrhea and/or sneezing with no identi-
fiable aetiology. IR is unrelated to allergy, infection, structural lesions, poly-
posis and or other systemic diseases(2).
Patients with nonallergic rhinitis with eosinophilia syndrome (NARES) form
another subgroup of nonallergic noninfectious perennial rhinitis patients.
They have significant mucosal eosinophilia (a nasal smear with more than
25% eosinophils(3)) and respond well to nasal corticosteroids(4). In previ-
ous studies, we hardly found any patients with NARES in our IR patient
groups, probably because we only selected IR patients in whom no therapeu-
tic effect had been achieved with nasal corticosteroids(5-7).
The pathophysiology of IR is largely unknown. It is assumed that neurogenic
mechanisms play an important role(8). Neuropeptides (CGRP, SP, etc.) are
released from peptidergic neurons in the nasal mucosa after activation by
unspecific stimuli, and can be responsible for the symptoms of IR(9-11).
Several studies have been published showing a therapeutic effect in IR pa-
tients for repeated topical applications of capsaicin(12-14). In recent papers,
we showed that repeated administration of capsaicin in a double blind pla-
cebo-controlled trial led to a significant and long-term reduction of symp-
toms(15, 16).
Repeated application of capsaicin, the pungent agent in hot pepper, is known
for its degeneration/desensitization effect on nonmyelinated peptidergic sen-
sory C-fibres, possibly explaining its therapeutic effect(17, 18).
In a previous biopsy study we did not find any significant difference in nasal
mucosa cell counts (T-lymphocytes, mast cells, IgE bearing cells, eosinophils
and langerhans cells) between capsaicin and placebo treated patients 2 weeks,
3 months and 9 months after therapy although there was a significant thera-
peutic effect measured with visual analogue scale (VAS). Also no significant
difference between both groups were found in pan-neurogenic staining of
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nasal mucosa using neurofilament and synaptophysine(6).
To our knowledge, until now, data concerning the provocation effect of cap-
saicin on nasal cellular homeostasis in humans is limited to lavage studies
following a single capsaicin application in allergic patients and healthy con-
trols(19, 20).
To get more insight into the pathophysiologic mechanism of IR and the direct
mode of action of capsaicin on nasal mucosa cell counts and neurogenic
staining we performed a double-blind placebo controlled nasal biopsy study
in 30 strictly selected and well-defined (Table 1) IR patients challenged
with either capsaicin or placebo. Biopsies were taken 2 weeks before
provocation at baseline (Biopsy I) and  15 minutes (biopsy II) and 1 hour
(biopsy III) after a single provocation with capsaicin or placebo. The cell
densities of T- lymphocytes(CD3, CD8, and CD25), mast cells(C-Kit,
chymase, and tryptase), basophils (BB1), IgE bearing cells and
eosinophils(BMK 13) and the neuronal staining with synaptophysine,
neurofilament, and vaniloid receptor ligand – 1 (VRL-1), the ‘capsaicin
receptor’(21) were studied in both layers of the nasal mucosa.
MATERIALS AND METHODS
Subjects
Patients were admitted to the study if they had a history of nasal complaints
such as nasal obstruction, sneezing and/or rhinorrhea for a period of over 1
year, which could not be attributed to allergic, nasal or paranasal infection,
anatomical disorders affecting nasal function, pregnancy or lactation and/or
systemic disorders (Table 1). They had to have used a nasal corticosteroid-
spray for at least 6 weeks without any beneficial effect on their nasal symp-
toms. They were non-smokers not using medication affecting nasal func-
tion. All patients underwent nasendoscopy and patients with nasal polyps
were excluded.
Patients with a diagnosis of IR scored their nasal complaints for a period of
2 weeks using a daily record chart (DRC) (Table 2). They were included in
the study if periods of either clear nasal discharge, and/or sneezing and/or
congestion persisted for an average of at least 1 hour a day for at least 5 days
during a period of 14 days (22). Thirty patients participated under conditions
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T able   1  Inclusion  and exclusion  criteria.
Inclusion  criteria
A ge betw een 16 and 65  years.
N egative Phadiatop  (Pharm acia , U ppsala , Sw eden)
S ym ptom s for m ore  than  1  year.
P eriods of nasal d ischarge, sneezing  and congestion  for an  average  of a t least 1  hour per
day for a t least 5  days during  a period  of 14  days.
N o beneficia l effec t of nasal corticostero id  spray  (for a period  of at least 6  w eeks)
E xclusion  criteria
U se of system ic  or inhaled  corticosteroids in  the previous m onth .
U se  of inhaled  sodium  crom oglycate or nedocrom il sodium  in  the  previous m onth .
U se  of astem izole  in  the  previous m onth .
Inability  of the  pa tien t to  stop  tak ing  m edication  affecting  nasal function .
A  serious and/or unstable d isease .
S m oking (in  the  previous 6  m onths)
N asal surgery  in  the previous 6  w eeks.
N asal polyps or a  h istory  of nasal polyps.
S ignificant anatom ical abnorm alities affecting  nasal function .
N asal o r paranasa l s inus in fection (abnorm al s inus X -ray).
P regnancy or lacta tion
T a b l e  2 .  D e s i g n  o f  t h e  d a i l y  r e c o r d  c h a r t  f o r  d e f i n i n g  n a s a l  s y m p t o m s  i n  I R  p a t i e n t s .
P o s s i b l e  s c o r e s  o n  t h e  d a i l y  r e c o r d  c h a r t
N a s a l  b l o c k a g e :
( n o t  b e i n g  a b l e  t o  b r e a t h e  f r e e l y  t h r o u g h  t h e
n o s e )
C l e a r  n a s a l  d i s c h a r g e :  ( r u n n y  n o s e )
0  =  a b s e n t
1  =  b e t w e e n  0 - 1 h  p e r  h a l f  d a y
2  =  b e t w e e n  1 - 2  h  p e r  h a l f  d a y
3  =  m o r e  t h a n  2  h  p e r  h a l f  d a y
S n e e z i n g
C o u g h i n g
0  =  a b s e n t
1  =  l e s s  t h a n  5  p e r i o d s  p e r  h a l f  d a y
2  =  b e t w e e n  5 - 1 0  p e r i o d s  p e r  h a l f  d a y
3  =  m o r e  t h a n  1 0  p e r i o d s  p e r  h a l f  d a y
G r e e n / Y e l l o w  m u c u s  p r o d u c t i o n : 0  =  a b s e n t
1  =  p r e s e n t
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of informed consent (male/female: 14/16); mean age was 36 years (16 – 65
years). Procedures were approved by the local Medical Ethics Committee.
Study design
Patients were randomized in a double-blind placebo-controlled fashion 1:1
allocated either to provocation with placebo or capsaicin 2 weeks after a
baseline biopsy (biopsy I) was taken. For this purpose a computer generated
randomization list was prepared in blocks of 8 randomly permuted allocations.
On the basis of this list the double-blind provocation medication(placebo or
capsaicin) was prepared by the local pharmacist. 15 minutes (biopsy II) and
1 hour (biopsy III) after provocation a nasal mucosa biopsy was taken. The
biopsy side for the baseline biopsy and the first biopsy 15 minutes after
provocation were independently randomized. The second nasal mucosa biopsy
1 hour after provocation (biopsy III) was taken at the contralateral side of the
first biopsy after provocation (biopsy II).
Provocation procedure
Provocation with capsaicin or placebo was preceded by three applications of
xylometazoline-hydrochloride 0.1% (OtrivinR nebulisator (1mg/ml Zyma,
Breda, Holland)) in each nostril for decongestion. The nasal mucosa was
then anaesthetized by three applications (10mg/puff) of lidocaine base
(100mg/ml, XylocaineR 10% spray (Astra, Rijswijk, Holland)) in each nos-
tril. To ensure good anaesthesia a pause of 15 minutes was introduced. The
lips, columella and philtrum were covered with a petrolatum/ lanolin/ glyc-
erin salve. The capsaicin solution (0.1 mmol/l) consisted of 30.3 mg pelargonic
acid vanillylamide dissolved in 3 ml alcohol (96%) and diluted in 1 l NaCl
solution (0.9%). As placebo, we used the capsaicin solvent only.
During provocation, 0.27 ml  of solution (three applications) was sprayed
into each nostril with a metered nasal spray (0.09 ml per actuation, coefficient
of variation 4%).
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Nasal biopsies
After randomization of the biopsy side (independently for biopsy I and II),
specimen of nasal mucosa were taken from the lower edge of the inferior
turbinate, about 2 cm posterior to the front edge, using a Fokkens forceps
(Explorent, Tubingen, Germany), formally called Gerritsma forceps, with a
cup diameter of 2.5 mm (23). Local anaesthesia was obtained by placing a
cotton-wool carrier with 50 mg of cocaine and one drop of adrenaline (1:1000)
under the inferior turbinate without touching the biopsy site. The specimen
were embedded in Tissue-Tek II O.C.T. compound and frozen immediately.
Staining procedures
Monoclonal antibodies (mAb) directed against synaptophysine,
neurofilament, CD3, CD8, CD25, C-Kit (CD 117), chymase, tryptase, BB1,
IgE and BMK 13 (Table 3)  were used together with the supersensitive
A n tib o d y S p e c if ic ity T itre S o u rc e
2 F 1 1 N e u ro fila m e n t 1 :5 0 S a n b io , U d e n , N L
S y 3 8 S y n a p to p h y sin e 1 :2 5 D ak o p a tts , IT K , U ith o o rn , N L
R ab b it
a n ti-V R L -
1
V R L -1 1 :7 0 C h e m ic o n , T e m e c u la , C a lif , U S A
L e u 4
L e u 2
C D 2 5
Y B 5 .B 8
C D 3
C D 8
IL 2 -r  (C D 2 5 )
C D  1 1 7
1 :2 5
1 :1 0 0
1 :1 5 0
1 :6 5
B e c to n  D ic k in so n , A lp h e n  a a n  d e  R ijn , N L
B 7
G 3
C h y m as e
T ry p ta s e
1 :1 0 0
1 :2 5 0
C h e m ic o n , T e m e c u la , C a lif , U S A
B B 1 Ig G 1 1 :1 5 0 A .F . W a lls , S o u th  H a m p to n
M H 2 5 -1 Ig E 1 :2 5 0 C e n tra l lab o ra to ry  o f  th e  N eth e r la n d s  R e d  C ro ss  B lo o d  T ran sfu s io n
se rv ic e  (C L B ), A m ste rd a m , N L
B M K 1 3 M B P 1 :2 0 0 S a n b io , U d e n , N L
Table 3. Monoclonal antibodies used to study the muscosal biopsies.
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immuno-alkaline phosphatase (ss-AP) method. Six micron thick serial sections
of nasal mucosa were cut on a Reichert-Jung 2800e frigocut cryostat (Leica)
and transferred to APES (amino-phosphate-ethylsilane) coated microscope
slides (Starfrost), dried and stored at minus 70° C. When slides were used
they were heated to room temperature, dried and fixed in ice cold acetone
for 10 minutes at room temperature.  They were then rinsed in phosphate-
buffered saline (PBS, pH 7.8), placed in a semi-automatic stainer (Sequenza,
Shandon), and incubated with normal goat serum (CLB, Amsterdam, the
Netherlands) for 10 minutes. For blocking of  endogenous avidine and biotin
all antibodies were diluted in 1% blocking reagent in PBS (Roche 10961760).
The sections were then incubated with the primary antibody for 60 minutes
at room temperature. After this the sections were rinsed with PBS for 5
minutes and incubated for 30 minutes with a biotinylated goat anti-mouse
(1:50) immunoglobuline antiserum (Biogenics, Klinipath, Duiven, the
Netherlands), rinsed successively in PBS and incubated with streptavidin ss-
AP (1:50) (Biogenics, Klinipath, Duiven, the Netherlands) for 30 minutes at
roomtemperature. Slides were then rinsed again in PBS and TRIS buffer
(0.2 mol/L, pH 8.5) and incubated for 30 minutes with new fuchsine (Chroma,
Kongen, Germany) substrate (containing levamisole to block endogenous
AP enzyme activity). Finally the sections were rinsed in distilled water,
counterstained with Gill’s hematoxylin and mounted in VectaMount (Vector,
Burlingame, CA). Control staining was performed by substitution with PBS
and incubation with an irrelevant mAb of the same subclass. Double staining
with tryptase and chymase was also performed in an alkaline phosphatase
procedure as previously described by our group (24). Staining with anti-
VRL-1 was done using tyramide signal amplification (25).
Light-microscopic evaluation
Stained cells were counted in two sections of each biopsy specimen. The
epithelium and lamina propria were evaluated separately. The total surface
area of the sections and their main parts (i.e. the epithelium and the lamina
propria) were estimated using the Leica Image Analysis System. The number
of cells/mm2 was calculated for the epithelium and the lamina propria.
The intensity, number and dimensions (width and length) of neuronal staining
was semiquantified.  Biopsies were ranked 1 to 30 by continuously comparing
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the biopsies amongst another until all were ranked. In practice: a section was
taken (at random), evaluated and put down. The next section was taken at
random and graded for stronger or weaker staining compared with the previous
section. At the end all sections were lined up.
Statistical analysis.
The Mann-Whitney U test was used to compare the distribution of the cell
counts between the two provocation groups. The exact chi-square trend test
was used to compare the ordinal score between the two provocation groups.
A p-value < 0.05 was considered to indicate a significant difference.
RESULTS
The application of Xylocaine 10% spray in the nasal airway was immediately
followed by a painful sensation that was described by all subjects as most
unpleasant. Patients did not complain of irritation of nose and lips during or
after capsaicin/placebo application. We feel this study was effectively blinded
for both patients and investigator.
Biopsy specimen
The sections of the nasal mucosa had an average surface area of 1.4 mm2
and usually had a lining of ciliated columnar epithelium with or without
goblet cells and/ or partially stratified cuboidal epithelium. The lamina pro-
pria usually consisted of a looser subepithelial cell-rich layer with most of
the mucous glands and a deeper collagenous cell-poor layer. The sections
were generally of good quality. All sections were sufficiently deep to assess
both layers. No structural damage to the mucosa was seen after capsaicin
provocation (thickness of the epithelium, thickness of basal membrane,
number and size of glands) either after 15 minutes or 1 hour.
It was not possible to evaluate two biopsy specimens. One exclusion was
made because the biopsy was to small  and the other specimen was displaced.
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Table 4a. and 4b.
Median cell numbers, 25th percentiles, and 75th percentiles for capsaicin (Caps) and pla-
cebo (Plac) provocation group of idiopathic rhinitis patients (both groups n=15) in epi-
thelium (4a) and lamina propria (4b).
Table 4a.
Median:
Epithelium Biopsy I
Run in
Biopsy II
15 min. after
provocation
Biopsy III
1 h after provocation
Plac Caps Plac Caps Plac Caps
CD3 198 170 155 215 104 248
25% 139 105 91 114 63 154
75% 337 216 254 371 167 287
CD8 118 142 192 118 128 121
25% 61 111 39 88 72 69
75% 236 204 241 257 180 307
CD25 13 10 12 16 14 17
25% 9 5 0 9 4 8
75% 36 51 25 35 31 38
C-Kit 13 9 23 14 19 8
25% 0 0 6 2 11 1
75% 39 31 45 52 29 29
Chymase 0 0 0 0 0 0
25% 0 0 0 0 0 0
75% 0 0 0 0 0 0
Tryptase 0 0 0 0 0 0
25% 0 0 0 0 0 0
75% 2 0 3 5 5 1
Try/Chym 3 1 3 5 0 4
25% 0 0 0 0 0 0
75% 21 8 36 14 26 13
BB1 0 0 0 0 0 0
25% 0 0 0 0 0 0
75% 0 0 0 0 0 0
IgE 102 27 42 128 37 41
25% 1 0 11 7 0 14
75% 160 148 206 191 167 80
BMK 13 5 0 7 8 5 8
25% 0 0 0 0 0 3
75% 22 13 35 22 18 29
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Inflammatory cells
The results are shown in tables 4a en 4b. The mAB-ss-AP staining showed
red cells against a blue counterstained background. T-lymphocytes, small round
cells, were abundantly present in the epithelium as well as in the lamina
propria. Sometimes clusters of T-cells were found in the epithelium or lamina
propria. The occurrence of these clusters did not differ between the groups.
Mast cells and basophils  were found mostly in the lamina propria and hardly
Table 4b.
Median:
Lamina
propria
Biopsy I
Run in
Biopsy II
15 min. after
provocation
Biopsy III
1 h after provocation
Plac Caps Plac Caps Plac Caps
CD3 345 404 294 291 298 370
25% 246 246 164 172 218 333
75% 444 644 466 695 393 428
CD8 125 177 121 169 130 169
25% 89 129 96 118 101 121
75% 224 272 161 258 180 213
CD25 21 33 31 45 24 47
25% 16 8 10 19 12 25
75% 28 57 39 89 54 67
C-Kit 84 32 88 87 57 46
25% 42 25 57 50 41 19
75% 93 59 129 129 93 77
Chymase 1 2 3 3 1 1
25% 0 0 0 0 0 0
75% 6 4 6 6 5 6
Tryptase 3 2 9 6 6 3
25% 1 0 2 1 3 1
75% 8 5 16 9 15 5
Try/Chym 125 96 135 135 127 115
25% 83 71 102 108 95 61
75% 149 118 207 185 170 157
BB1 0 1 1 1 1 1
25% 0 0 0 0 0 0
75% 2 3 4 3 3 5
IgE 109 64 105 144 107 90
25% 24 9 56 60 55 33
75% 143 105 235 187 211 127
BMK 13 17 10 30 18 23 46
25% 6 5 11 5 6 4
75% 42 20 72 39 44 83
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ever in the epithelium. Eosinophils were hardly ever present in this material.
Sometimes moderate infiltrates were found in the lamina propria. Again the
occurrence did not differ between the groups.
Only for CD3 in the epithelium 1 hour after provocation a significant higher
cell count was found in the capsaicin group using the Mann-Whitney U test.
Due to multiple testing the p-value of 0.011 for CD3 could have been easily
caused by chance.
Neuronal staining
The staining for synaptophysine, neurofilament and VRL-1 showed red fibres
cut at different angles. For VRL, synaptophysine and neurofilament no
significant differences were found between the two provocation groups using
the exact chi-square trend test.
DISCUSSION
The therapeutic effect of capsaicin in strictly selected IR patients has repeat-
edly been demonstrated by our group and others (12-16) and has been intro-
duced in our daily clinical practice. Unfortunately the mode of action of cap-
saicin and the aetiology of IR still remains uncertain.
Nasal capsaicin provocation results in rhinorrhea, nasal blockage and sneez-
ing (26). This sensory neural stimulation may produce these effects either
through a orthodromic, central neural reflex, associated with efferent
parasympathetic neurotransmission, and or via anti-dromic release of
neuropeptides from sensory neurons (27). Repeated applications of capsai-
cin, however, lead to desensitization and even degeneration of peptidergic
unmyelinated sensory C-fibres(18, 28).
Therefore the hypothesis, suggested by Wolf, that an hyperactive non-adren-
ergic non-cholinergic peptidergic neuronal system is the underlying patho-
physiology in IR may offer an explanation for the beneficial effect of capsai-
cin with these patients.
This hypothesis was corroborated by Lacroix, who reported an increased
concentration of neuropeptides in a group of  chronic IR patients(11), im-
provement of symptoms by local treatment of capsaicin giving a 50% reduc-
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tion in CGRP-Li content in nasal biopsies (17), and a correlation between
symptom intensity and CGRP-Li concentration in nasal mucosa (29).
In our previous work we did not find any significant difference between
mucosal inflammatory cellular infiltrates of symptomatic IR patients and
healthy controls (5, 7). This in contrast with allergic rhinitis where mucosal
inflammatory cellular infiltrates are correlated with nasal complaints (30,
31). In two other studies, we failed to ascertain a relation between the number
of immunocompetent cells and nasal complaints in IR patients. A significant
reduction of immunocompetent cells in the nasal mucosa of IR patients treated
with nasal steroids (fluticasone aqueous nasal spray) was not accompanied
by a reduction in nasal complaints(32) and, inversely, a significant reduction
in nasal complaints in a group of IR patients treated with topical capsaicin
aqueous nasal spray was not accompanied by a change in inflammatory me-
diators (15) or a reduction/change in the numbers of inflammatory cells in
nasal mucosa biopsies 2 weeks, 3 months, and 9 months after the treatment
period (6).
In the present study we did not find any significant difference in nasal mu-
cosa cell counts and neurogenic staining 15 minutes and 1 hour after provo-
cation. The difference found for CD3 in the epithelium 1 hour after provoca-
tion is interpreted by us as caused by chance (multiple testing). This strength-
ens us in our idea that inflammatory cells do not play a role in the mode of
action of capsaicin and the aetiology of IR.
It is therefore not surprising, that our findings are in contrast with the results
of nasal challenge with capsaicin in subjects with allergic rhinitis. Philip
described biphasic inflammatory-cell influx with neutrophils, eosinophils
and mononuclear cells in nasal lavage upto 4 hours following capsaicin provo-
cation in ten patients with allergic rhinitis and in 10 healthy controls (20).
Roche described an increase in neutrophils 10 minutes after capsaicin chal-
lenge in eight patients with allergic rhinitis but not in eight healthy controls
(19). Whether or not this reflects a ‘wash out’ by increased nasal secretion,
an increase in mucociliary activity which could sweep cells out of the si-
nuses, or a transmigration of immunocompetent cells from the vessels through
the nasal mucosa in the nasal lumen remains open for discussion (20).
Neither Roche nor Philip anaesthetized the nasal mucosa prior to the capsai-
cin administration.
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The inflammatory-cell influx they found after capsaicin provocation, as op-
posed to our results, might well be caused by a protective orthodromic, cen-
tral neural reflex due to the nociceptive stimulation (pain) of capsaicin in
combination with  allergic nasal inflammation. In our model this reflex will
be blocked by the local anaesthesia applied prior to capsaicin provocation,
possibly preventing this protective inflammatory-cell influx. Whether this
reflex and or an anti-dromic release of neuropeptides from sensory neurons
was the underlying mechanism for their post capsaicin inflammatory-cell
influx remains open for debat, the more so as Roche, as opposed to Philip,
did not found this inflammatory-cell influx in the healthy control group.
These and previous findings, however, do not discard Wolfs hypothesis of a
hyperactive non-adrenergic non-cholinergic peptidergic system, as the ac-
tivity of this system was not measured. A functional hyperactivity of this
system, not captured by histological changes, could still be the underlying
pathophysiological process in IR also providing an explanation for the nasal
hyperreactivity in IR demonstrated with cold dry air provocation (33) and the
significant reduction in hyperreactivity up to 9 months after capsaicin therapy
(16).
Another possibility, raised by Sanico, is a hyper- or dysaesthesia at the cen-
tral nervous system (CNS) level as an explanation for IR (8). This would
explain why we do not find any significant differences in cell counts and
neurogenic staining between capsaicin and placebo provocation in this study
and between IR patients and normals. According to this theory a functional
or numerical downregulation of the nonmyelinated peptidergic sensory C-
fibres would explain the therapeutic effect of intranasal capsaicin applica-
tion (8).
To quantify neuronal staining is difficult as nerve fibres may have a different
diameter and can be cut at different angels, resulting in an abundant, “spa-
ghetti like”, variation in staining morphology. Therefore (small) alterations
in the peptidergic neuronal system might not have been detected in this study.
We cannot exclude the possibility that we overlooked the presence of other
allergies, not assessed in our patients. Moreover, it has been hypothesised
that IR is based on a local, occult allergy (34-36). The diagnosis of IR is
made by exclusion. An allergy test is not 100% sensitive and absence of
systemic manifestations of atopic disease, such as a positive skin prick test
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or RAST, may not reflect the processes in the nose - a small shock organ.
However, in seasonal or perennial allergic rhinitis, increased numbers of
inflammatory cells, such as Langerhans cells, IgE positive cells, basophils
and eosinophils, can be found in the nasal mucosa as a sign of inflammation
(25, 30, 37). In this strictly selected group of IR patients we did not find any
of the histological characteristics of allergic rhinitis or NARES (Table 4a
and 4b). We therefore discard local allergy or NARES as being the underly-
ing pathophysiology for IR in this group of patients.
We conclude that capsaicin, after local anaesthesia of the nasal mucosa, does
not affect cellular homeostasis or neurogenic staining 15 minutes and 1 hour
after nasal provocation in this double-blind placebo controlled biopsy study.
This strengthens us in our idea that inflammatory cells do not play a role in
the mode of action of capsaicin and the aetiology of IR.
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CHAPTER VIII
General discussion and conclusions
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INTRODUCTION
Although our knowledge about nonallergic noninfectious rhinitis and its
possible cause has increased the last decades, still about 50% of the patients
with  nonallergic noninfectious rhinitis has to be classified as suffering from
idiopathic rhinitis, or rather e causa ignota. This, combined with the limited
and frequently insufficient treatment options available, remains a frustrating
burden for almost every clinically active ENT specialist and allergologist,
let alone all idiopathic rhinitis (IR) patients, often seeking second and third
opinions because of continuing complaints despite up to date treatment. The
care for the IR patients and the above-mentioned frustration with the often
disappointing results of treatments available were the guidelines for the
research described in this thesis.
EVOLUTION IN NOMENCLATURE
The publication of the the ''World Health Organisation Initiative, Allergic
Rhinitis and its Impact on Asthma''  (ARIA) in 2001 brought more clarity
about the nomenclature of nonallergic rhinitis (1). In accordance with this
publication the term idiopathic rhinitis (IR) is now commenly used in the world
literature to describe syndromes of chronic rhinitis with an unknown aetiology.
Before this important initiative almost every research group used its own
description. For example IR was formerly referred to by us as NANIPER (2),
where nowadays NANIPER is used as a collective term to describe all, known
and unknown, nonallergic noninfectious perennial rhinitis syndromes, among
others encompassing IR. Other terms, like NINAR (noninfectious, nonallergic
rhinitis) (3), intrinsic rhinitis (4), hypertrophic rhinitis (5) and vasomotor
rhinitis (6), are also purely descriptive and should not longer be used to
prevent misunderstandings. Therefor, and for the sake of clarity and uniformity,
the term NANIPER, used in the original articles forming Chapter III and VI,
was replaced with idiopathic rhinitis.
125
DIAGNOSTIC CRITERIA FOR IDIOPATHIC RHINITIS
To exclude all known prevailing causes of chronic rhinitis one should at least take
a proper history (medication, smoking in previous 6 months, occupation, etc.),
adequately exclude commonly occurring inhalation allergies (skin prick test and or
specific serum IgE measurement) and perform rhinoscopia anterior and
nasendoscopy to exclude gross anatomical aberrations and nasal polyps.
The mucosa of the nose and sinus are contiguous and thus chronic nasal complaints
can also be induced by a (accompanying) chronic sinusitis. When in doubt of a
possible chronic sinusitis one should not hesitate to perform CT-scan imaging.
However, if the history and the nasendoscopy lack criteria pointing at possible
sinus problems, CT-scan imaging is not obligatory for diagnosing IR.
Nasal complaints as a IR selection-criterion
After having excluded all known causes of chronic rhinitis one is left with a
group of patients with nasal complaints of unknown pathology (IR). This
means that the studied patient group is probably a melting pot of patients
suffering from nasal complaints, with presumably variable pathogenesis.  To
study, select and define a group of patients, and more, measure the effects of
interventions, positive criteria are needed to make the group as homogeneous
as possible.  As IR is solely diagnosed on patients complaints we use (and
have used in all our previous studies to IR) a daily record chart on which
patients have to reach a minimum symptom score to be classified as IR patient.
The minimum is set using as a basis the definition of rhinitis put forward by
Mygind and Weeke (8). In affected patients, periods of nasal discharge,
sneezing and / or congestion have to persist for an average of at least 1 hour
per day on at least five days during a period of fourteen days.
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FACTS AND HYPOTHESES ON IDIOPATHIC RHINITIS, HOW DO
THE DATA FROM THIS THESIS FIT WITHIN
Pathophysiology:
Chronic inflammation
One of the proposed pathophysiological mechanisms for IR includes a chronic
inflammatory disorder of antigenic (local allergy) or neurogenic nature (9-
11). A pivotal characteristic in the pathophysiological concept of inflamma-
tion is an influx of inflammatory cells in the affected tissue. Knani reported
increased mediator levels in IR suggesting an involvement of inflammatory
cells (12). Mast cells were implicated by Abe and Terrahe (13, 14). How-
ever, Braunstein and Hua failed to find any evidence for neurogenically in-
duced mast cell degranulation. Despite the fact that substance P can induce
histamine release from isolated human skin mast cells in vitro, it does not so
in the human nasal mucosa or in rat trachea in vivo (15, 16). Also the gener-
ally sub-optimal result of antihistamine therapy in IR patients tells against an
important role of histamine in the pathophysiology of IR (17).
In symptomatic allergic rhinitis patients, an increase of inflammatory cells
has been observed in the nasal mucosa and this increase is positively corre-
lated to nasal complaints (18-20).
In chapter V we did not found any significant difference for nasal mucosal
lymphocytes, antigen-presenting cells, eosinophils, macrophages, monocytes,
mast cells and other IgE-positive cells between IR patients and controls.
In chapter III and VI, we failed to ascertain a relation between the number of
immunocompetent cells and nasal complaints in IR patients. A significant
reduction in nasal complaints in a group of IR patients treated with topical
capsaicin aqueous nasal spray was not accompanied by a change in inflam-
matory mediators or a reduction in the numbers of inflammatory cells. Fur-
thermore, Blom found a significant reduction of immunocompetent cells in
the nasal mucosa of IR patients treated with nasal steroids (fluticasone aque-
ous nasal spray) that was not accompanied by a reduction in nasal complaints
(7).
In chapter VII no significant differences in nasal mucosa cell counts, between
the capsaicin and placebo provocated group, were found 15 minutes and 1
hour after intranasal provocation in a double-blind placebo controlled bi-
opsy study.
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Considering the aforementioned we conclude that inflammatory cells are not
involved in our meticulously selected, non smoking, IR patient groups and
that a chronic inflammatory disorder (e.g. local allergy) does not seem to be
one of the important pathophysiological mechanisms in IR. We also conclude
that NARES patients were not included in our IR patient groups because
eosinophils are not found in the mucosa of our patients.
The NANC-hypothesis
One of the prevailing hypotheses nowadays concerning the pathophysiology
of IR is the one, among others suggested by Wolf (21), holding a hyperactive
nonadrenergic noncholinergic (NANC) peptidergic neural system responsi-
ble for the pathophysiology in IR (further summarised as the NANC-hypoth-
esis). One of the firsts to suggest the NANC-hypothesis in IR was Lundblad
in 1983, extrapolating study results on rat nasal mucosa with substance P and
capsaicin (22).
The NANC-hypothesis was corroborated by Lacroix, who reported an in-
creased concentration of neuropeptides in a group of  chronic IR patients
(23), improvement of symptoms by local treatment of capsaicin giving a 50%
reduction in CGRP-Li content in nasal biopsies (24), and a correlation be-
tween symptom intensity and CGRP-Li concentration in the nasal mucosa
(25).
Perivascular and intra-epithelial NANC-sensory nerve fibres contain
neuropeptides (including VIP, substance P (SP), calcitonin gene related pep-
tide (CGRP), id.) which are demonstrated in the nasal mucosa of various
mammals including man (26, 27). The actions of these neuropeptides are
limited by neutral endopeptidase degradation (28). These neuropeptides are
locally released from peptidergic neurons (antidromic release), mainly un-
myelinated sensory C-fibres, in the nasal mucosa after activation by unspe-
cific stimuli, and can be responsible for the symptoms of IR (5, 23, 29).
Stimulation can be induced by inflammatory mediators, like histamine and
bradykinin but also by a number of inhaled irritants like nicotine, cigarette
smoke, formaldehyde and capsaicin (30-32).
With the exemption of Lacroix's study, reporting an increased concentration
of neuropeptides in a group of chronic IR patients (23), solid proof that the
NANC-hypothesis forms one of the underlying pathophysiologic mechanisms
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in IR in human beings is still lacking. The fact that intranasal capsaicin is an
effective therapy in the majority of IR patients, reported by several authors in
the last decade (33-35), is till now probably the hardest indication for the
role of the NANC-hypothesis in IR.
In our histology studies we did not find any significant difference in pan-
neurogenic staining of nasal mucosa using neurofilament and synaptophysine
between capsaicin and placebo treated patients 2 weeks, 3 months and 9
months after therapy (chapter VI) although there was a significant therapeutic
effect measured with visual analogue scale (chapter 3). Also Wolf was un-
able to show a reduction of NANC-fibres in the nasal mucosa of IR patients
after successful capsaicin treatment (33) using monoclonal antibodies di-
rected against SP, VIP and polyclonal antibodies against CGRP and NPY.
Fang reported on neuropeptide tissue concentrations and neuroendocrine cell
densities in normals and IR patients (5). No significant differences were found.
Unfortunately, in spite of elegant neuropeptide quantification methods, patients
were simple characterized as suffering from chronic hypertrophic rhinitis
without mentioning of any in- or exclusion criteria.
In chapter VII no significant differences were found between the capsaicin
and placebo provocated group in nasal mucosa neurogenic staining using
monoclonal antibodies directed against synaptophysine, neurofilament and
VRL-1, 15 minutes and 1 hour after intranasal provocation.
With the exception of VRL-1, we used pan-neurogenic markers, not allowing
discrimination between the adrenergic, cholinergic and or the peptidergic
system. Also quantifying neuronal staining is difficult as nerve fibres may
have a different diameter and can be cut at different angels, resulting in an
abundant, 'spaghetti like', variation in staining morphology. Therefore small
alterations in the peptidergic neuronal system might have been missed.
The main problem with using histology in studying the role of the NANC-
hypothesis in IR is that one is only looking for inferential evidence, as the
activity of the system itself is not measured. Therefore our lack of positive
histology criteria regarding the NANC-hypothesis in IR may not let us con-
clude that this hypothesis does not play an important role in IR. It might well
be that capsaicin exerts its effect of sensory neuropeptide depletion by receptor
modulation instead of neurotoxity. Wolf  suggested capsaicin receptor block-
age as a possible explanation for the capsaicin treatment effect (33). Al-
though sounding attractive it seems improbable that capsaicin receptor blockage
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alone can result in the long lasting therapeutic effect for capsaicin observed
in IR patients.
Recapitulating, and keeping in mind the beneficial action of intranasal capsaicin
in IR, one can state that the NANC-hypothesis probably forms one of the
important pathophysiological mechanisms underlying IR, although decisive
data is still missing.
Hyper- or dysesthesia at the CNS level
Another possibility, raised by Sanico, is a hyper- or dysesthesia at the central
nervous system (CNS) level as an explanation for IR (3). An abnormally
increased nasal perceptual acuity as the underlying pathophysiology in IR
would explain the lack of changes/differences in cell counts and neurogenic
staining in the several studies mentioned above. According to this theory a
functional or numerical downregulation of the unmyelinated peptidergic sen-
sory C-fibres would also explain the therapeutic effect of intranasal capsai-
cin application, reducing perceptive signals to the sensory cortex (3). One
might speculate that the central 'nasal perception gauge' is re-adjusted by a
vicious circle of environmental irritants and changes in atmospheric condi-
tions, perceived as an ever irritating stimulans at the CNS level, giving rise
to the protective responses hereupon like rhinorrhea, vascular congestion and
sneezing.
Sounding attractive this "hyperesthesia at the CNS level" probably plays a
role in the IR pathology, as CNS neuronal plasticity may play a role in other
chronic diseases like headache and low backpain (36, 37). Neuronal hyper-
excitability, which apparently is a key phenomenon in many types of chronic
pain, can result in changes in the nervous system from the level of the periph-
eral nociceptor to the highest cortical centers in the brain (38).
Whether it really forms a solitary subtype of IR will be very difficult to prove
due to the key role allocated to the central nervous system (CNS) in this
theory. Elaborating on this theme one might consider treating IR patients with
CNS directed medication like antidepressants or other neuro-modulating agents
trying to achieve a resetting of the central 'nasal perception gauge'.
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Pollutional and meteorological factors:
Epidemiological studies traditionally focused on the relationship of
meteorolgical conditions, pollution and pollen with symptoms of bronchial
hyperreactivity, asthma and allergy (39-41). In a recent article Braat et al
focused on the relation between complaints in IR patients and meteorological
factors(42). He showed that minor pollution and meteorological disturbances
can result in substantial changes in nasal reactivity symptoms in IR patients
but not in controls. An increasing number of in- and outdoor pollutants is
recognised as being irritative for the nasal mucosa. Among these are dust,
ozone, black smoke, sulfur dioxide, volatile organic compounds,
formaldehyde, and environmental tobacco smoke (43-45). Whether there is a
relationship between frequent/longlasting exposure to these agents and the
development of IR is unknown although there is some circumstantial
experimental evidence of impaired nasal function after exposure in laboratory
settings (46-48). Whether the increased nasal hyperreactivity in IR patients to
these agents is post or propter remains open for further investigations.
Nasal Hyperreactivity:
Nasal hyperreactivity to non-specific stimuli is a common and characteristic
feature of patients with chronic rhinitis. Hyperreactivity only describes the
increased reactivity of the nasal mucosa to 'nonspecific'stimuli such as smoke,
strong odors and other irritants but does not point to any cause of the disease.
In addition, patients with allergic rhinitis usually complain of hyperreactivity
to non-allergic stimuli, obviously as a direct result of allergic inflammation
(49). Several studies showed a positive correlation between nasal
hyperreactivity and airway inflammation in allergic rhinitis (50-52). Patients
with ongoing allergic rhinitis seem to be in a continuous late phase state of
eosinophilia and increased mediator release, a condition that can explain
priming and nonspecific hyperreactivity of the nasal mucous membrane (53,
54).
With his publication on CDA provocation in 1998 (55), our dear and recently
too young deceased colleague dr. Braat provided us with a grateful used
(Chapter IV), diagnostic tool for measuring hyperreactivity and monitoring
treatment effect in IR.
In chapter IV we found, along with a significant decrease in visual analogue
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scores for nasal complaints, a significant reduction in cold dry air dose re-
sponsiveness up to 9 months after start of intranasal capsaicin treatment, re-
flecting a decrease in nasal hyperreactivity. Taking into account the accompa-
nying absence of a significant change in peak nasal inspiratory flow (PNIF)
and acoustic rhinometry, and the fact that the values of PNIF and acoustic
rhinometry did not differ from values found in normal controls, it is our opin-
ion that one of the most important characteristics that results in symptoms in
IR patients is increased hyperreactivity of the nasal mucosa rather than de-
creased patency.
This seems to be in agreement with the observation of a significant increase
in nasal airway resistance after 3 repeated forced expirations through the
nose in IR patients but not in healthy controls (56). Likewise, no significant
differences were found between baseline nasal airway resistance and peak
nasal expiratory flow rate measurements in IR patients and healthy controls
in this study.
CDA challenge is a natural stimulus, although exposure conditions are artificial.
CDA is thought to provoke neurogenic reflex mechanisms in the nasal mucosa
(31, 57). This, combined with the significant reduction in cold dry air dose
responsiveness up to 9 months after start of intranasal capsaicin treatment
found in chapter IV, also points in the direction of the NANC hypothesis, that
a hyperactive nonadrenergic noncholinergic peptidergic neural system is the
underlying pathophysiology in IR.
Capsaicin desensitisation in patients with perennial allergic rhinitis to house dust
mite (HDM) with a comparable treatment protocol as was used in the study
of chapter III was lacking therapeutic effect in a placebo controlled trial (72).
Probably the nasal hyperreactivity induced by an allergic inflammation, such
as HDM allergic rhinitis, is mainly dominated by inflammatory events (a
continuous late phase state of eosinophilia and increased mediator release)
and thereby not modified by interference at the level of C-fibers.
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CAPSAICIN THERAPY AND ITS SAFETY IN IDIOPATHIC
RHINITIS
The unmyelinated sensory C-fibres or 'pain receptors' are specifically sensi-
tive to capsaicin (8-methyl-N-vanillyl-6-nonenamide), the pungent agent of
hot red pepper (58, 59). Nasal capsaicin provocation results in rhinorrhea,
nasal blockage and sneezing(60). This sensory neural stimulation may pro-
duce these effects either through an orthodromic, central neural reflex, asso-
ciated with efferent, predominantly parasympathetic, neurotransmission, and
or via an antidromic, afferent, local release of neuropeptides from sensory
neurons (22). Repeated applications of capsaicin lead to desensitisation and
even degeneration of peptidergic unmyelinated sensory C-fibres (61, 62) pos-
sibly explaining its therapeutic effect in IR. The efficiency of capsaicin in IR
has been reported on by many authors (33-35) but was still not generally
accepted, and much less applied, as one of the treatment options in IR.  In
chapter III and IV we showed in a double-blind placebo controlled fashion
that intranasal capsaicin application ameliorates nasal symptoms for at least
9 months. It is our opinion that with these studies objective and hard data has
been provided concerning the favourable effect of intranasal capsaicin in IR.
However, direct observations explaining the efficacy and working mecha-
nisms of capsaicin are still lacking, comparable and in parallel with the lack
of knowledge about the pathophysiology of IR. Although classical observa-
tions on functional desensitisation of nociceptors by capsaicin may explain
its beneficial effects, the recent discovery of a range of receptors which re-
spond to capsaicin, menthol, and temperature and their expression in subsets
of sensory nerve fibres, provides an exciting prospect towards advancing our
understanding and treatment of IR and the more precise modes of action of
capsaicin (63-65).
In chapter IV no significant changes in safety data (smell, blood pressure,
heart rate) were found during and after a treatment period of 10 days with
intranasal capsaicin once every second or third day for a total of five appli-
cations. This observation, combined with the fact that up to the writing of this
discussion we never had any serious and or late adverse event after intrana-
sal capsaicin treatment (N = 150 approximately till now) nor are there any
known to us from the literature, allows us to conclude that intranasal capsai-
cin is safe to use.
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This is supported by data from other medical specialities. Recently intrana-
sal capsaicin cream and civamide solution (the vanilloid receptor agonist
cis-capsaicin), in comparable concentrations have been used as a (preven-
tive) treatment during an episodic cluster headache period without local an-
aesthesia (66, 67). The most common, and of course expected, adverse events
included nasal burning and lacrimation. As with our studies, no systemic
side-effects were observed. The same accounts for intravesical capsaicin
instillations in comparable concentrations for the treatment of interstitial cys-
titis (68).
Most of our IR patients treated with capsaicin (with or without a trial connec-
tion) are still satisfied after a one year follow up and thereby discharged. The
few capsaicin treated patients that did come back with a return of their com-
plaints, after having been succesfully discharged one year after the capsaicin
treatment,  all showed a renewed positive reaction to capsaicin therapy (un-
published data).
In a 1995 review article Y.J Surh and S.S Lee critically examined findings in
the literature of studies testing a possible carcinogenic, cocarcinogenic and
or anticarcinogenic activity of capsaicin (73). Ingestion of large amounts of
capsaicin has been reported to cause histopathological and biochemical
changes, including erosion of gastric mucosa and hepatic necrosis (74). Nu-
merous investigations have been conducted, mainly on laboratory animals
and ex vivo, to determine the potential mutagenic and carcinogenic activity of
capsaicin and chilli pepper, but results are discordant. Whether capsaicin is
anticarcinogenic or carcinogenic and what makes this hot substance anti- or
carcinogenic still remains unknown (73).
The idea that minute quantities of capsaicin might be carcinogenic seems
unlikely to us for it is the natural ingredient of hot-pepper consumed daily by
billions of people, especially in Asiatic countries. If  there should be even the
smallest carcinogenic potency in capsaicin, one might expect a higher inci-
dence of these carcinomas in these countries with a large hot-pepper con-
sumption or in labourers in the ‘hot-pepper’industry.
A recent hospital based case-control study conducted in Mexico revealed
that high-level consumers of chilli peppers (90-250 mg of capsaicin per day)
had an increased risk of gastric cancer compared to low-level chilli pepper
consumers (0-29.9 mg of capsaicin per day) (75).  Besides the methodologi-
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cal considerations one can have with this study, it remains unclear whether
capsaicin present in hot chilli-pepper is the major causative factor in the
aetiology of gastric cancer in human beings. Other causative factors might be
confounders like other hot-chilli ingredients, increased alcohol consumption
with the hot meals, etc.
Recapitulating, we don’t think that an one-time treatment of five intranasal
capsaicin applications at one-hour intervals of less than 1 mg per application,
maintains any carcinogenic risk what so ever.
SPECULATIONS ON FUTURE RESEARCH
Capsaicin therapy
In our opinion the one day capsaicin treatment, described in Chapter IV, marks
a step forward in the therapy of IR patients not reacting to topical steroids.
Due to the relative ease to administer this one day capsaicin treatment at the
outpatient clinic we are also hopeful that others, notably the first and second
echelon, will introduce this treatment in their practice and will corroborate
our findings in the near future.
Another interesting capsaicin treatment regimen is the one suggested by Eberle
(69) in which patients apply a low-dose intranasal capsaicin solution 3 times
a day during a period of 4 weeks at home without local anaesthesia. He found
a marked reduction in symptoms (although not quantified) without significant
side effects in 61 IR patients. Unfortunately, in a recent double-blind placebo
controlled pilot study, we did not find a positive treatment effect after a 6
week treatment period of 3 times a day intranasal self administration of a
capsaicin 10-6 M solution (unpublished data). Maybe we did not find any
positive treatment effect because of a too low capsaicin concentration (0.0273
microgram per actuation in contrast with Eberle who used a capsaicin spray
of 0.125 microgram per actuation) . We chose this low concentration because
we wanted to conduct the study in a placebo controlled way without local
anaesthesia. Further research has to show whether intranasal self administra-
tion of a low dose capsaicin solution is preferable to the present one day
capsaicin treatment regimen and, in that case, which capsaicin concentration
suites best with regard to therapeutic effect and patient tolerance. Also a
combination of previous schemes can be imagined.
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One might also consider to use capsaicin as a treatment for IR patients
favourably reacting to topical steroids. In view of our practical capsaicin
application schedule one might speculate about a double-blind placebo
controlled trial comparing this one day capsaicin application regimen with
daily local corticosteroids for a period of for instance 6 weeks. It would be
very interesting to know whether this group also favourably reacts to capsaicin
or not and whether there are histological differences between the group of IR
patients favourably and unfavourably reacting to local corticosteroids.
Pathophysiology
In view of our repeatedly negative histological study results regarding the
NANC-hypothesis in IR (neurogenic staining) it may be more worthwhile to
conduct quantitative studies into neuropeptide content of the nasal mucosa.
Like Lacroix (23) one can use radioimmunoassay techniques to measure
neuropeptide concentrations (like SP, CGRP and VIP) in weighed homogenized
rapidly frozen samples of nasal mucosa. It would be very interesting to perform
these measurements on nasal mucosa samples of IR patients before and after
capsaicin provocation and before and after treatment. Results may well shed new
light on the validity of the NANC-hypothesis in IR and the working mechanism of
capsaicin.
Also, as mentioned before, much can be expected from the recent discovery
of a range of receptors which respond to capsaicin, menthol, and tempera-
ture and their expression in subsets of sensory nerve fibres. More insight
into sensory dysfunction at the receptor level  provides new prospect to-
wards advancing our understanding and treatment of IR and the more pre-
cise modes of action of capsaicin (63-65).
With regards to the possible "hyperesthesia at the CNS level" one might speculate
on performing function MRI or PET scan studies before and after provocation in
IR patients and controls. Whether these neuro-activity image techniques are
already sensitive enough to measure differences at such a specific level may
be wondered but it would be an interesting exploration into the role of the
CNS in IR, although expensive.
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PROSPECTS
Now that one of the problems concerning further research into IR is tackled,
namely the developing of a commonly agreed on nomenclature (1), hopefully
funding agencies and research groups are more willing to put extra effort into
the examination of the pathophysiology (-ies) of IR in the near future. Al-
though fundraising for this topic has shown to be very difficult in recent years.
Most charitable institutions and non-profit organisations rather spend their
money on 'more important, better measurable' medical problems than on
people suffering from some nasal catarrh. Hereby doing injustice to the mil-
lions of sufferers who are left without any understanding of the reasons be-
hind their complaints. It also surpasses the fact of the poor quality of life
status in IR patients, comparable with those suffering from asthma (70), and
the impact of nasal complaints on social life (71S).
The fact that capsaicin is a free obtainable product that cannot be patented,
makes it uninteresting for the pharmaceutical industry to sponsor research
into this field. The advantage of this is that every local/hospital pharmacist
should be able to deliver an intranasal capsaicin solution. This makes the introduction
of capsaicin therapy for IR patients in daily practice a realistic goal,
independent of this same industry.
CONCLUDING REMARKS:
- According to our histological outcome parameters we were able to
select a well defined group of IR patients.
- NARES patients were not included in our IR patient groups, probably
because of a good response of these patients to intranasal
corticosteroids.
- Local, intranasal capsaicin is a safe and effective therapy in IR.
- Five intranasal capsaicin applications at 1-h intervals on a single day
are at least as effective in treating idiopathic rhinitis as five capsaicin
applications once every second or third day and with that, more patient
and physician friendly.
- Intranasal CDA provocation results in increased mucus production and
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Summary
In chapter I the currently known causes for nonallergic noninfectious rhinitis
and possible treatments are summarised. Also possible pathophysiological
mechanisms underlying idiopathic rhinitis (IR) are discussed.
In chapter II the aims of the studies are presented. This thesis comprises
studies aimed at the therapeutic potential and safety of intranasal capsaicin in
IR patients, developing a patient and physician friendly, effective intranasal
capsaicin treatment regimen for IR and the histological analysis of the nasal
mucosa of IR patients in order to find an explanation for the therapeutic effect
of capsaicin and the underlying pathophysiology of IR.
In chapter III the efficacy of intranasal capsaicin spray in the treatment of IR
patients was studied. Several authors described capsaicin, the pungent sub-
stance in red-pepper, as an efficacious therapy for IR. Repeated intranasal
capsaicin application induces peptide depletion and specific degeneration
of the unmyelinated sensory C-fibers in the nasal mucosa. We performed a
double-blind placebo (NaCl 0.9%) controlled study with 25 IR patients. Daily
record charts (DRC) and visual analogue scales (VAS) were used for clinical
evaluation. Nasal lavages were obtained before, during and after treatment.
There was a significant and long-term reduction in the VAS scores in the
capsaicin group. No significant difference was found between the placebo
and capsaicin treated groups for the mean group concentrations of leukotriene
(LT) C4 / D4 / E4 , prostaglandin D2 (PGD2), and tryptase. The levels of mast
cell mediators, tryptase and PGD2, and leukotrienes, mediators derived from
a variety of inflammatory cells, were low at baseline and comparable with
levels observed in nasal lavages obtained from normals. As involvement of
inflammation could not be demonstrated, it is not surprising that capsaicin
has no effect on inflammatory mediators. This suggests that inflammatory
cells do not play a major part in the pathogenesis of IR.
In chapter IV we conducted a double-blind  double-dummy parallel group
trial to determine whether a more practical capsaicin application schedule is
equally effective as the one described in chapter III. In daily practice, this
application regimen of intranasal capsaicin application once every second or
third day for a total of 7 days proved to be impractical because of the large
number of visits required in a short period of time. Thirty patients were
145
randomized into two different treatment regimens: one group received cap-
saicin five times the first day at one-hour intervals. This was followed by a
placebo dummy once every second or third day for a total of five treatments 2
weeks after the capsaicin application (group A). The other group (B) re-
ceived the placebo dummy five times on the first day followed by capsaicin
once every second or third day for a total of five treatments 2 weeks after the
placebo application. The VAS scores for overall nasal symptoms, rhinorrhea
and nasal blockage showed significant decrease after the start of treatment in
both groups, with a significantly  steeper decrease in group A. A significant
reduction in cold dry air dose responsiveness was also found up to 9 months
after therapy in both groups, reflecting a decrease in nasal hyperreactivity.
No significant changes in safety data (smell, blood pressure, heart rate) were
found. We conclude that local capsaicin nasal spray significantly reduces
nasal complaints in IR patients and that five treatments of capsaicin on a
single day is at least as effective as five treatments of capsaicin in 2 weeks,
and even more effective in the reduction of nasal complaints measured with
VAS. We also conclude that intranasal capsaicin seems safe to use.
In chapter V nasal mucosa inflammatory cell densities of IR patients are stud-
ied and compared with normals. Mucosal inflammatory cellular infiltrates
are correlated with nasal complaints in symptomatic allergic rhinitis. Some
authors suggest inflammation of neurogenic or immunogenic nature as the
underlying pathophysiology for IR. We examined whether inflammatory cells
are involved in the pathogenesis of IR. Nasal biopsies were taken of 65
patients with significant nasal complaints and 20 controls without nasal com-
plaints. Inflammatory cells were quantified, using monoclonal antibodies di-
rected against lymphocytes, antigen presenting cells, eosinophils, macrophages,
monocytes, mast cells and other IgE-positive cells. No significant differ-
ences were found, for any cell, between IR patients and controls. We con-
clude that inflammatory cells do not seem to play an important role in this
meticulously characterised group of IR patients.
In chapter VI the long term effects of capsaicin spray on the nasal mucosa are
studied. Capsaicin has been shown previously to reduce nasal complaints in
patients with IR. Proposed pathophysiologic mechanisms for IR include a
chronic inflammatory disorder of antigenic or neurogenic nature as well as
the possibility of a functional neuronal disorder. We hypothesized that the
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beneficial effect of capsaicin might be the result of a down regulation of
inflammation (by a reduction of inflammatory cells) or through a modulation
of neural tissue density. Patients were treated with either a placebo or cap-
saicin spray solution once every second or third day for a total of seven
treatments. Both sides were treated each visit. Biopsies were taken before, 2
weeks after, 3 months after and 9 months after the treatment period. Immu-
nohistochemical staining of the biopsy specimen was performed to ascertain
the effect of treatment on immunocompetent cell densities (quantitative)
and neural tissue densities (semiquantitative) in the nasal mucosa. Nasal com-
plaints were significantly reduced in the capsaicin treated group (Chapter
III). The number of lymphocytes, antigen presenting cells, eosinophils,
macrophages, monocytes, mast cells and other IgE-positive cells did not sig-
nificantly differ between the capsaicin and the placebo group. No significant
differences between both groups were found in pan-neurogenic staining of
nasal mucosa using neurofilament and synaptophysine. To conclude capsai-
cin intranasal spray does significantly improve nasal symptomatology in IR
patients (shown previously), without affecting cellular homeostasis or over-
all neurogenic staining upto 9 months after treatment. Immunocompetent cells
are not involved in IR.
In chapter VII we tried to get more insight into the pathophysiologic mecha-
nism of IR and the direct mode of action of capsaicin on nasal mucosa cell
counts and neurogenic staining. To our knowledge data concerning the provo-
cation effect of capsaicin on nasal cellular homeostasis in humans is limited
to lavage studies following a single capsaicin application in allergic patients
and healthy controls. We performed a double-blind placebo controlled nasal
biopsy study in 30 strictly selected and well-defined IR patients challenged
with either capsaicin or placebo. Biopsies were taken at baseline 2 weeks
before provocation and  15 minutes and 1 hour after a single provocation
with capsaicin or placebo. The cell densities of CD3, CD8, CD25, C-Kit,
chymase, tryptase, BB1, IgE and BMK 13 and the neuronal staining with
synaptophysine, neurofilament and VRL-1 were studied in both layers of the
nasal mucosa. No significant difference in nasal mucosa cell counts and
neurogenic staining were found 15 minutes and 1 hour after provocation.
Only for CD3 in the epithelium 1 hour after provocation a significant higher
cell count was found in the capsaicin group using the Mann-Whitney U test.
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Due to multiple testing this p-value of 0.011 for CD3 could have been easily
caused by chance. We conclude that capsaicin, after local anaesthesia of the
nasal mucosa, does not affect cellular homeostasis or neurogenic staining 15
minutes and 1 hour after nasal provocation in this double-blind placebo con-
trolled biopsy study. This strengthens us in our idea that inflammatory cells
do not play a role in the mode of action of capsaicin and the aetiology of IR.
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Samenvatting
In Hoofdstuk I worden de momenteel bekende oorzaken en behandelingen
van niet allergische, niet infectieuze perenniale rhinitis beschreven. Ook
worden mogelijk aan idiopathische rhinitis (IR) ten grondslag liggende
oorzaken besproken en bediscussieerd.
In Hoofdstuk II worden de doelstellingen van dit proefschrift beschreven. Dit
proefschrift omvat studies naar het therapeutisch effect en veiligheid van
intranasale capsaicine spray bij IR patiënten, het ontwikkelen van een patiënt
en behandelaar vriendelijk, effectief capsaicine toedieningsschema voor de
behandeling van  IR en de histologie van neusslijmvlies biopsieën van IR
patiënten ter verklaring van het therapeutisch effect van capsaicine bij IR en
de aan IR ten grondslag liggende pathofysiologie.
In Hoofdstuk III wordt het therapeutisch effect van capsaicine spray bij IR
patiënten bestudeerd. Capsaicine, het hete bestanddeel van rode peper, wordt
door verschillende auteurs beschreven als een effectief middel bij IR.
Herhaalde intranasale capsaicine applicaties induceren neuropeptide depletie
en specifieke degeneratie van de niet gemyeliniseerde sensibele C-afferente
vezels in het neusslijmvlies. Bij 25 patiënten werd een dubbelblinde placebo
(NaCl 0.9%) gecontroleerde studie verricht. Dagkaarten en visual anlogue
scales (VAS) werden gebruikt voor klachtenregistratie en  klinische evaluatie.
Voor, en na gedurende behandeling werden neuslavages verricht. Er werd
een lang aanhoudende, significante afname van neusklachten gevonden, gemeten
met VAS, in de met capsaicine behandelde groep. Er werd geen significant
verschil gevonden tussen de met placebo en capsaicine behandelde groep
voor de gemiddelde groep concentraties van leukotrienen C4/D4/E4,
prostaglandine D2  en tryptase. De uitgangsconcentraties van mestcel
mediatoren, tryptase en prostaglandine D2, en leukotrienen, mediatoren
afkomstig van een verscheidenheid aan inflammatoire cellen, waren laag en
vergelijkbaar met concentraties gevonden in neusspoelingen bij normale
controles. Daar betrokkenheid van inflammatie niet kon worden aangetoond,
is het niet verwonderlijk dat capsaicine geen effect heeft op
ontstekingsmediatoren. Dit suggereert dat inflammatoire cellen geen grote rol
spelen in de pathogenese van IR.
In Hoofdstuk IV werd een dubbelblinde dubbeldummie parallelle groepen
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studie verricht, om uit te zoeken of een praktischer capsaicine
toedieningsschema even effectief zou zijn als die beschreven in Hoofdstuk
III. In de dagelijkse praktijk blijkt dit toedieningsschema van intranasale
capsaicine spray toediening iedere tweede of derde dag voor een totaal van 7
behandelingen onpraktisch door de vele bezoeken in een korte periode. Dertig
patiënten werden gerandomiseerd over 2 behandelgroepen: de ene groep werd
de eerste dag vijf keer, om het uur, behandeld met capsaicine. Twee weken
hierna volgde behandeling met een placebo dummie een keer per dag iedere
tweede of derde dag voor een totaal van 5 behandelingen (groep A). De
andere groep (B) werd eerst behandeld met de placebo dummie vijf keer op
de eerste dag, 2 weken later gevolgd door capsaicine behandeling een keer
per dag iedere tweede of derde dag voor een totaal van 5 behandelingen. De
VAS scoren voor algemene neusklachten, loopneus en neusverstopping lieten
een significante verbetering zien na aanvang van de therapie in beide groepen,
met een significant sterkere verbetering in groep A. Ook werd er een
significante afname van de reactie op koude droge lucht provocatie gevonden
tot en met 9 maanden na behandeling in beide groepen, wijzend op een afname
in nasale hyperreactiviteit. Er werden geen significante veranderingen
gevonden in de onderzochte veiligheidsparameters (reuk, bloeddruk, hartslag).
Wij concluderen dat capsaicine neusspray de neusklachten van IR patiënten
significant vermindert en dat vijf capsaicine behandelingen op een dag
minstens zo effectief zijn als vijf capsaicine behandelingen in 2 weken, en
zelfs effectiever in de vermindering van neusklachten gemeten met VAS.
We concluderen ook dat de behandeling met intranasale capsaicine spray
veilig lijkt.
In Hoofdstuk V worden de dichtheden van ontstekingscellen in neusslijmvlies
van IR patiënten bestudeerd en vergeleken met die in normale controles.
Infiltratie van ontstekingscellen in neusslijmvlies correleert met neusklachten
in symptomatische allergische rhinitis patiënten. Inflammatie van neurogene
dan wel immunogene aard wordt door sommige auteurs als het onderliggend
lijden in IR gezien. Wij onderzochten of ontstekingscellen betrokken zijn bij
de pathogenese van IR. Van 65 patiënten met significante neusklachten en
20 normale controles zonder neusklachten werden neusslijmvlies biopsieën
genomen. Met behulp van monoklonale antistoffen gericht tegen lymfocyten,
antigeen presenterende cellen, eosinofielen, macrofagen, monocyten,
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mestcellen en andere IgE-positieve cellen werden de ontstekingscellen
gekwantificeerd. Voor geen enkele cel werden er significante verschillen
gevonden tussen de IR patiënten en de normale controles. Wij concluderen
dat ontstekingscellen geen belangrijke rol lijken te spelen in deze streng
geselecteerde groep van IR patiënten.
In Hoofdstuk VI worden de lange termijn effecten van capsaicine spray op het
neusslijmvlies van IR patiënten bestudeerd. Van capsaicine is aangetoond
dat het afname van neusklachten geeft bij patiënten met IR (zie ook Hoofdstuk
III en IV). Veronderstelde pathogenetische mechanismen omvatten een chronisch
inflammatoire aandoening van antigene dan wel neurogene aard of wel een
functioneel neurologisch lijden. Wij onderzochten of het therapeutische effect
van capsaicine mogelijk veroorzaakt wordt door een afname van inflammatie
(vermindering van ontstekingscellen) of door een verandering van de dichtheid
in zenuwweefsel in het neusslijmvlies. Patiënten werden behandeld met pla-
cebo of capsaicine spray (0.15 mg capsaicine per neusgat) iedere tweede of
derde dag voor een totaal van 7 behandelingen. Elk bezoek werden beide
zijden van de neus behandeld. Voorafgaand aan en 2 weken, 3 maanden en 9
maanden na de behandelingsperiode werd er een neusslijmvlies biopsie
genomen. De coupes van deze biopsieën werden immunohistochemisch
gekleurd om het effect van de behandeling op immunocompetente cel
dichtheden (kwantitatief) en zenuwweefsel dichtheid (semi-kwantitatief) te
bepalen. De neusklachten waren significant verbeterd in de met capsaicine
behandelde patiënten groep zoals beschreven in Hoofdstuk III. Het aantal
lymfocyten, antigeen presenterende cellen, eosinofielen, macrofagen,
monocyten, mestcellen en andere IgE-positieve cellen lieten geen significant
verschil zien tussen de met capsaicine en placebo behandelde groep. Ook
werden er geen significante verschillen gevonden tussen beide groepen na
pan-neurogene kleuringen van de  neusslijmvlies biopten met behulp van de
neuromarkers neurofilament en synaptofysine. Concluderend geeft capsaicine
een significante verbetering van neusklachten in IR patiënten (eerder
aangetoond), zonder effect op inflammatoire cellen in, of pan-neurogene
kleuringen van neusslijmvlies biopten tot en met 9 maanden na behandeling.
Immunocompetente cellen zijn niet betrokken bij IR.
In Hoofdstuk VII hebben we getracht meer inzicht te krijgen in de
pathofysiologische mechanismen van IR en de directe werking van capsaicine
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op neusslijmvlies cel tellingen en neurogene kleuring. Voor zover wij na kunnen
gaan zijn studies naar het provocatie effect van capsaicine op cel homeostase
in het neusslijmvlies van mensen beperkt gebleven tot neuslavage studies na
een enkele capsaicine spray applicatie bij allergische patiënten en gezonde
controles. Wij verrichtten een dubbelblinde placebo gecontroleerde studie
naar neusslijmvlies biopsieën van 30 streng geselecteerde en goed
gedefinieerde IR patiënten die werden geprovoceerd met capsaicine of pla-
cebo. Twee weken voor en 15 minuten en 1 uur na een enkele capsaicine of
placebo provocatie werden de neusslijmvlies biopsieën afgenomen. De cel
dichtheden van cellen aangekleurd op CD3, CD8, CD25, C-Kit, chymase,
tryptase, BB1, IgE en BMK 13 en zenuwweefsel dichtheid na neurogene
kleuring met synaptofysine, neurofilament en VRL-1 werden bestudeerd in
beide lagen van het neusslijmvlies. Er werden geen significante verschillen
gevonden in cel aantallen of neurogene kleuring in de biopsieën afgenomen
15 minuten en 1 uur na provocatie. Alleen voor CD3 in het epitheel 1 uur na
provocatie werd een significant hoger cel aantal gevonden in de met capsaicine
geprovoceerde groep met behulp van de Mann-Whitney U statistische test.
Gezien het multipele testen in deze studie zou deze p-waarde van 0.011 heel
wel door toeval veroorzaakt kunnen zijn. Wij concluderen dat capsaicine, na
lokale verdoving van het neusslijmvlies, geen effect heeft op cel homeostase
of neurogene kleuring 15 minuten en 1 uur na neusprovocatie in deze
dubbelblinde placebo gecontroleerde biopsie studie. Dit versterkt ons idee
dat ontstekingscellen geen rol spelen in het werkingsmechanisme van
capsaicine en de etiologie van IR.
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List of abbreviations
NANIPER nonallergic noninfectious perennial  rhinitis
IR idiopathic rhinitis
NARES nonallergic rhinitis with eosinophilia syndrome
CGRP calcitonin-gene-related-peptide
SP substance-P
DRC daily record chart
VAS visual analogue scale
UPSIT                University of Pennsylvania smell identification test
PNIF peak nasal inspiratory flow
MCA minimal cross-sectional area
MMCA mean of the minimal cross-sectional area
TMMCA sum of right and left MMCA
CI confidence interval
SD standard deviation
BP blood pressure
HR heart rate
VRL-1 vaniloid receptor ligand -1
CD cluster of differentiation
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Dankwoord
De onderzoeken beschreven in dit proefschrift werden verricht op de polikliniek KNO
van het Dijkzigt ziekenhuis Rotterdam en het KNO laboratorium van de Erasmus
Universiteit Rotterdam.Vrijwel iedereen werkzaam op deze afdelingen is direct of
indirect betrokken geweest bij de totstandkoming van dit proefschrift en allen ben ik
hoogst erkentelijk. Ondanks enkele tegenslagen en het feit dat een en ander naast de
opleiding moest gebeuren kijk ik met plezier en tevredenheid terug op het leerzame
proces dat geleid heeft tot dit proefschift.
Een aantal personen wil ik hier met name noemen:
- Prof. dr. W.J. Fokkens. Beste Wytske, dank voor je voortdurend vertrouwen en
steun, ook als het eens tegen zat. Zoals je ziet heb je gelijk gekregen. Jammer
dat je Rotterdam hebt verlaten, veel plezier en succes toegewenst in
Amsterdam.
- Prof. dr. C.D.A. Verwoerd. Tijdens mijn eerste KNO college als derdejaars
medicijnen student maakte u reeds een grote indruk op mij door uw heldere en
duidelijke betoog. Ik beschouw het als een voorrecht voor u te hebben mogen
werken.
- Dr. H.M. Blom. Beste Henk (en Maja natuurlijk), for better and for worse,
dank voor je begeleiding maar nog veel meer voor je vriendschap. Je hebt je
belofte waargemaakt.
- Dr. R. Gerth van Wijk. Beste Roy, bij jou op de allergologie is het allemaal
begonnen. Dank voor je stabiele aanwezigheid, je was er altijd als ik je nodig
had.
- De leden van de promotiecommissie, Prof. dr. H.C. Hoogsteden, Prof. dr. P.J.
Koudstaal en Prof. dr. P. van Cauwenberge, wil ik hartelijk danken voor het
lezen en beoordelen van de leesversie van dit proefschrift.
- Prof. dr. F.W.H.M. Merkus. Hartelijk dank voor het plaatsnemen in de grote
promotiecommissie en uw interesse in capsaicine.
- Prof. dr. L. Feenstra. Dank voor de ruimte die u mij bood, met name tijdens de
zeer leerzame stage in Gooi-Noord, mijn proefschrift af te ronden.
- Geachte Patienten. Dank voor jullie betrokkenheid en de over het algemeen
berustende gelatenheid waarmee alle neusslijmvliesbiopsieën genomen
mochten worden.Gelukkig hebben de meesten van jullie veel baat ondervonden
bij de capsaicine, iets dat al het werk niet voor niets heeft gemaakt en ook
steeds een belangrijk motiverende kracht is geweest voor ons allemaal. Door
jullie ben ik mij pas echt gaan beseffen wat voor een enorm negatieve impact
neusklachten op iemands dagelijks leven kunnen hebben.
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- Dr. E. Rijntjes. Beste Evert, Oudjaarsavond 1999 zal ik nooit vergeten. Je
maakte mij toen duidelijk dat je het voor minder dan een promotie niet zou
doen. Alsjeblieft.
- Dr. P.G.H. Mulder. Beste Paul, zonder jouw professionele en persoonlijke
betrokkenheid zou er van de statistische onderbouwing van onze onderzoeken
weinig zijn terechtgekomen. Gelukkig dronken we samen altijd een goede
cappucino (de beste verkrijgbaar in heel het complex kwamen we achter
tijdens de zomersluiting van de koffiebar) en hadden en hebben we als bijna
buren ook diverse andere onderwerpen met elkaar te bespreken zodat ik altijd
met plezier de statistiek bij je kwam doen.
- Wijle Drs J.P.M. Braat. Beste Verio, zonder jouw boekje (met dank aan Dr.
Hans de Groot) had dit boekje ook niet geschreven kunnen worden. Met name
het lopend krijgen en wetenschappelijk onderbouwen van de koude droge lucht
provocatie heb jij voor elkaar gekregen waarvoor grote dank en bewondering.
Moge je rusten in vrede.
- Drs. J.M. Keizer en Drs. E.L. Werger-Boeke. Beste Laura en Jos, zoals jullie
als geen ander weten brengt elk klinisch onderzoek zeer veel werk met zich
mee. Patienten zien, onderzoeken, behandelen, begeleiden, etc. etc. Nooit was
iets te veel en jullie stonden altijd voor de patienten en mij klaar. Jammer dat
jullie geen KNO-arts willen worden maar dat jullie goede artsen zijn weet ik
zeker. Hartelijk dank!
- Zusters en Administratie. Beste Carma, Evy, Charles, Yvet, Edwin, Charlie en
alle anderen (ook Mariam en de andere dames op de Allergologie bedoel ik
hiermee), voor jullie bestonden er geen problemen maar alleen oplossingen.
Niets was onmogelijk, patienten in het weekend of ’s avonds laat zien, geen
probleem, de statussen lagen altijd klaar. Fijn dat de bureaucratie op jullie nog
geen post had gevat, zoals jullie zien hebben we het niet voor niets gedaan.
- Lab. Beste Alex, Liesanne, Esther en alle anderen. Dank voor al jullie
monnikken werk en blijvend vertrouwen / enthousiasme in de goede afloop.
Zoals jullie weten ben ik nooit echt een labmens geweest en zal ik het denk ik
ook wel nooit worden.
- Dr. S. van der Baan, dr. P.H.M.T. Olde Kalter en dr. H.D. Vuyk. Beste Bert,
Peter en last but not least HD, dank voor de vrije tijd die jullie mij gunden om
de laatste hoofdstukken te schrijven. Echter veel meer dank nog voor alle
puntjes op de i van mijn chirurgische vaardigheden, in verband hiermee denk ik
nog bijna wekelijks aan jullie. Met name ook de mogelijkheid mij bij jullie te
bekwamen in de plastische en reconstructieve aangezichtschirurgie beschouw
ik als een groot voorrecht. Ook mocht ik jullie graag pesten met die Gooise
KNO patiente die alleen voorhoofdspijn had als ze met open cabriodak reed.
Het ga jullie goed.
- Mw. de Braal, bibliothecaresse Gooi Noord. Door u kon ik mijn literatuur
kennis up to date houden. Zelfs artikelen uit verre landen en lang vergeten
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tijden wist u te achterhalen. Ik ken geen academische bibliotheek waar een en
ander zo soepel loopt als op uw afdelingtje (ondanks bezuinigingen en
managementsaanvallen). Hulde!
- Mw. en Dhr. Bhoelai. Lieve Lila en Henk, na mijn moeders overlijden zijn
jullie, en in het begin natuurlijk voornamelijk Lila, op de achtergrond een
enorme steun en toeverlaat voor mij geweest. Ik had een en ander nooit zo
voor elkaar kunnen krijgen zonder jullie betrokkenheid bij mijn (en die van
mijn broers) wel en wee, waarvoor mijn hartelijke dank.
- Wijle mijn ouders. Lieve Pa en Ma, dank voor alle energie en betrokkenheid.
Hoe ouder ik word, hoe meer ik het begin te snappen.
- Prof. dr. Tj. Peters en Mw. dr. B. Peters-Kümmerly en Mw. dr. T.J. Peters.
Beste Tjerk , Barbara en Tjitske, dank voor jullie hulp en steun bij het uitgeven
van dit boekje. Een oude familie traditie mag ik wel zeggen. Veel grotere dank
echter voor het feit dat ik jullie dochter mocht huwen en hierbij gelijk 2 fijne
ouders en een zus erbij kreeg (en natuurlijk ook voor de immer aanwezige,
overheerlijke, Zwitserse “ufeine, guete Schoggichügeli”).
- Broers. Lieve Okke en Bas, ik ben erg blij met en trots op jullie. Achteraf
gezien eigenlijk ongelooflijk hoe we ons er doorheen hebben geworsteld /
gewerkt. Ik hoop er altijd voor jullie te zijn, maar nooit meer paternalistisch.
- Dr. N.S. van Rijswijk-Peters. Lieve Nien, “Liefste Groatje, ain’t no mountain
high enough”!!!
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Levensloop
Jeroen Bernard van Rijswijk werd op 14 april 1971 te Berekum, Ghana
geboren. In 1989 haalde hij het V.W.O. diploma aan de Rijks
Scholengemeenschap in Middelharnis. Hetzelfde jaar begon hij aan de studie
Chemische Technologie te Delft. Van 1990 tot en met 1997 studeerde hij
geneeskunde aan de Erasmus Universiteit Rotterdam. In augustus 1997 ving
hij aan als arts-assistent KNO aan het Dijkzigt Ziekenhuis Rotterdam onder
leiding van professor Verwoerd, eerst als AGNIO en later in opleiding, die in
oktober 2003 werd afgerond. De basis voor het onderzoek dat resulteerde in
dit proefschrift werd gelegd tijdens het geneeskunde afstudeerproject onder
leiding van H.M. Blom en verder uitgebouwd tijdens de KNO-assistenten
periode.
Sinds januari 2004 is hij naar volle tevredenheid werkzaam als vrij gevestigd
KNO-arts, met als aandachtsgebied de esthetische en reconstructieve
aangezichtschirurgie, in het van Weel-Bethesda ziekenhuis te Dirksland in
associatie met D. van Hasselt.
Hij is gehuwd met Nienske Sophie van Rijswijk-Peters.
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